Gene "Gene synonym" Ensembl "Gene description" Uniprot Chromosome Position "Protein class" "Biological process" "Molecular function" "Disease involvement" Evidence "HPA evidence" "UniProt evidence" "NeXtProt evidence" "MS evidence" "RNA tissue specificity" "RNA tissue distribution" "RNA tissue specificity score" "RNA tissue specific NX" "RNA cell line specificity" "RNA cell line distribution" "RNA cell line specificity score" "RNA cell line specific NX" "RNA cancer specificity" "RNA cancer distribution" "RNA cancer specificity score" "RNA cancer specific FPKM" "RNA brain regional specificity" "RNA brain regional distribution" "RNA brain regional specificity score" "RNA brain regional specific NX" "RNA blood cell specificity" "RNA blood cell distribution" "RNA blood cell specificity score" "RNA blood cell specific NX" "RNA blood lineage specificity" "RNA blood lineage distribution" "RNA blood lineage specificity score" "RNA blood lineage specific NX" "RNA mouse brain regional specificity" "RNA mouse brain regional distribution" "RNA mouse brain regional specificity score" "RNA mouse brain regional specific pTPM" "RNA pig brain regional specificity" "RNA pig brain regional distribution" "RNA pig brain regional specificity score" "RNA pig brain regional specific pTPM" Antibody "Reliability (IH)" "Reliability (Mouse Brain)" "Reliability (IF)" "Subcellular location" "Secretome location" "Blood concentration - Conc. blood IM [pg/L]" "Blood concentration - Conc. blood MS [pg/L]" "Subcellular main location" "Subcellular additional location" "Antibody RRID" "Pathology prognostics - Breast cancer" "Pathology prognostics - Cervical cancer" "Pathology prognostics - Colorectal cancer" "Pathology prognostics - Endometrial cancer" "Pathology prognostics - Glioma" "Pathology prognostics - Head and neck cancer" "Pathology prognostics - Liver cancer" "Pathology prognostics - Lung cancer" "Pathology prognostics - Melanoma" "Pathology prognostics - Ovarian cancer" "Pathology prognostics - Pancreatic cancer" "Pathology prognostics - Prostate cancer" "Pathology prognostics - Renal cancer" "Pathology prognostics - Stomach cancer" "Pathology prognostics - Testis cancer" "Pathology prognostics - Thyroid cancer" "Pathology prognostics - Urothelial cancer" "Tissue RNA - adipose tissue [NX]" "Tissue RNA - adrenal gland [NX]" "Tissue RNA - amygdala [NX]" "Tissue RNA - appendix [NX]" "Tissue RNA - basal ganglia [NX]" "Tissue RNA - bone marrow [NX]" "Tissue RNA - breast [NX]" "Tissue RNA - cerebellum [NX]" "Tissue RNA - cerebral cortex [NX]" "Tissue RNA - cervix, uterine [NX]" "Tissue RNA - colon [NX]" "Tissue RNA - corpus callosum [NX]" "Tissue RNA - ductus deferens [NX]" "Tissue RNA - duodenum [NX]" "Tissue RNA - endometrium 1 [NX]" "Tissue RNA - epididymis [NX]" "Tissue RNA - esophagus [NX]" "Tissue RNA - fallopian tube [NX]" "Tissue RNA - gallbladder [NX]" "Tissue RNA - heart muscle [NX]" "Tissue RNA - hippocampal formation [NX]" "Tissue RNA - hypothalamus [NX]" "Tissue RNA - kidney [NX]" "Tissue RNA - liver [NX]" "Tissue RNA - lung [NX]" "Tissue RNA - lymph node [NX]" "Tissue RNA - midbrain [NX]" "Tissue RNA - olfactory region [NX]" "Tissue RNA - ovary [NX]" "Tissue RNA - pancreas [NX]" "Tissue RNA - parathyroid gland [NX]" "Tissue RNA - pituitary gland [NX]" "Tissue RNA - placenta [NX]" "Tissue RNA - pons and medulla [NX]" "Tissue RNA - prostate [NX]" "Tissue RNA - rectum [NX]" "Tissue RNA - retina [NX]" "Tissue RNA - salivary gland [NX]" "Tissue RNA - seminal vesicle [NX]" "Tissue RNA - skeletal muscle [NX]" "Tissue RNA - skin 1 [NX]" "Tissue RNA - small intestine [NX]" "Tissue RNA - smooth muscle [NX]" "Tissue RNA - spinal cord [NX]" "Tissue RNA - spleen [NX]" "Tissue RNA - stomach 1 [NX]" "Tissue RNA - testis [NX]" "Tissue RNA - thalamus [NX]" "Tissue RNA - thymus [NX]" "Tissue RNA - thyroid gland [NX]" "Tissue RNA - tongue [NX]" "Tissue RNA - tonsil [NX]" "Tissue RNA - urinary bladder [NX]" "Tissue RNA - vagina [NX]" "Tissue RNA - B-cells [NX]" "Tissue RNA - dendritic cells [NX]" "Tissue RNA - granulocytes [NX]" "Tissue RNA - monocytes [NX]" "Tissue RNA - NK-cells [NX]" "Tissue RNA - T-cells [NX]" "Tissue RNA - total PBMC [NX]" "Cell RNA - A-431 [NX]" "Cell RNA - A549 [NX]" "Cell RNA - AF22 [NX]" "Cell RNA - AN3-CA [NX]" "Cell RNA - ASC diff [NX]" "Cell RNA - ASC TERT1 [NX]" "Cell RNA - BEWO [NX]" "Cell RNA - BJ [NX]" "Cell RNA - BJ hTERT+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]" "Cell RNA - CACO-2 [NX]" "Cell RNA - CAPAN-2 [NX]" "Cell RNA - Daudi [NX]" "Cell RNA - EFO-21 [NX]" "Cell RNA - fHDF/TERT166 [NX]" "Cell RNA - HaCaT [NX]" "Cell RNA - HAP1 [NX]" "Cell RNA - HBEC3-KT [NX]" "Cell RNA - HBF TERT88 [NX]" "Cell RNA - HDLM-2 [NX]" "Cell RNA - HEK 293 [NX]" "Cell RNA - HEL [NX]" "Cell RNA - HeLa [NX]" "Cell RNA - Hep G2 [NX]" "Cell RNA - HHSteC [NX]" "Cell RNA - HL-60 [NX]" "Cell RNA - HMC-1 [NX]" "Cell RNA - HSkMC [NX]" "Cell RNA - hTCEpi [NX]" "Cell RNA - hTEC/SVTERT24-B [NX]" "Cell RNA - hTERT-HME1 [NX]" "Cell RNA - HUVEC TERT2 [NX]" "Cell RNA - K-562 [NX]" "Cell RNA - Karpas-707 [NX]" "Cell RNA - LHCN-M2 [NX]" "Cell RNA - MCF7 [NX]" "Cell RNA - MOLT-4 [NX]" "Cell RNA - NB-4 [NX]" "Cell RNA - NTERA-2 [NX]" "Cell RNA - PC-3 [NX]" "Cell RNA - REH [NX]" "Cell RNA - RH-30 [NX]" "Cell RNA - RPMI-8226 [NX]" "Cell RNA - RPTEC TERT1 [NX]" "Cell RNA - RT4 [NX]" "Cell RNA - SCLC-21H [NX]" "Cell RNA - SH-SY5Y [NX]" "Cell RNA - SiHa [NX]" "Cell RNA - SK-BR-3 [NX]" "Cell RNA - SK-MEL-30 [NX]" "Cell RNA - T-47d [NX]" "Cell RNA - THP-1 [NX]" "Cell RNA - TIME [NX]" "Cell RNA - U-138 MG [NX]" "Cell RNA - U-2 OS [NX]" "Cell RNA - U-2197 [NX]" "Cell RNA - U-251 MG [NX]" "Cell RNA - U-266/70 [NX]" "Cell RNA - U-266/84 [NX]" "Cell RNA - U-698 [NX]" "Cell RNA - U-87 MG [NX]" "Cell RNA - U-937 [NX]" "Cell RNA - WM-115 [NX]" "Blood RNA - basophil [NX]" "Blood RNA - classical monocyte [NX]" "Blood RNA - eosinophil [NX]" "Blood RNA - gdT-cell [NX]" "Blood RNA - intermediate monocyte [NX]" "Blood RNA - MAIT T-cell [NX]" "Blood RNA - memory B-cell [NX]" "Blood RNA - memory CD4 T-cell [NX]" "Blood RNA - memory CD8 T-cell [NX]" "Blood RNA - myeloid DC [NX]" "Blood RNA - naive B-cell [NX]" "Blood RNA - naive CD4 T-cell [NX]" "Blood RNA - naive CD8 T-cell [NX]" "Blood RNA - neutrophil [NX]" "Blood RNA - NK-cell [NX]" "Blood RNA - non-classical monocyte [NX]" "Blood RNA - plasmacytoid DC [NX]" "Blood RNA - T-reg [NX]" "Blood RNA - total PBMC [NX]" "Brain RNA - amygdala [NX]" "Brain RNA - basal ganglia [NX]" "Brain RNA - cerebellum [NX]" "Brain RNA - cerebral cortex [NX]" "Brain RNA - hippocampal formation [NX]" "Brain RNA - hypothalamus [NX]" "Brain RNA - midbrain [NX]" "Brain RNA - olfactory region [NX]" "Brain RNA - pons and medulla [NX]" "Brain RNA - thalamus [NX]" ABCG4 WHITE2 ENSG00000172350 "ATP binding cassette subfamily G member 4" Q9H172 11 119149012-119162653 "Predicted intracellular proteins, Predicted membrane proteins, Transporters" Transport "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "brain: 20.7;parathyroid gland: 7.4;retina: 7.5;testis: 7.2" "Cell line enhanced" "Detected in some" "AN3-CA: 5.6;HAP1: 3.0;U-2 OS: 2.9" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA057635 Enhanced "HPA057635: " "unprognostic (3.26e-2)" "unprognostic (4.75e-4)" "unprognostic (6.31e-2)" "unprognostic (1.83e-3)" "unprognostic (3.76e-2)" "unprognostic (3.66e-2)" "unprognostic (1.13e-1)" "unprognostic (9.35e-2)" "unprognostic (1.67e-1)" "unprognostic (9.07e-2)" "unprognostic (3.29e-2)" "unprognostic (8.78e-2)" "unprognostic (2.25e-1)" "unprognostic (4.15e-4)" "unprognostic (2.26e-1)" "unprognostic (6.48e-3)" "unprognostic (2.65e-3)" 0.7 1.6 3.9 0.7 5.7 0.3 0.4 20.7 12.8 0.8 0.8 0.8 0.0 0.9 1.1 1.3 1.9 0.6 1.2 2.2 4.9 6.6 0.8 0.5 0.5 0.5 4.7 5.2 0.5 1.2 7.4 0.3 0.7 12.7 0.9 0.7 7.5 0.4 2.0 0.4 1.2 0.7 1.4 1.5 0.5 0.5 7.2 0.5 0.6 1.5 0.0 1.5 0.7 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 1.4 1.2 5.6 0.8 0.0 0.1 0.2 0.1 0.7 1.5 0.0 0.1 0.0 0.6 0.2 0.5 3.0 0.3 0.7 0.3 1.0 1.0 0.1 0.0 1.9 0.0 1.6 0.5 0.0 1.0 0.0 1.2 0.1 0.1 0.9 0.2 0.4 0.0 2.4 0.6 0.1 0.0 0.1 0.0 0.0 0.5 1.1 1.7 0.2 0.1 0.4 0.0 0.2 0.4 2.9 0.5 0.2 0.3 0.3 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.9 5.7 20.7 12.8 4.9 6.6 4.7 5.2 12.7 0.5 ANKS1B "AIDA-1, ANKS2, cajalin-2, EB-1" ENSG00000185046 "Ankyrin repeat and sterile alpha motif domain containing 1B" Q7Z6G8 12 98726457-99984654 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "brain: 66.2;skeletal muscle: 28.2" "Cell line enhanced" "Detected in some" "AF22: 11.8;ASC TERT1: 7.0;SCLC-21H: 12.9" "Cancer enhanced" "Detected in some" "glioma: 1.6" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA044628, HPA078230" Enhanced Supported "Vesicles,Plasma membrane,Cytosol" "Plasma membrane, Cytosol" Vesicles "HPA044628: , HPA078230: " "unprognostic (5.50e-2)" "unprognostic (3.26e-2)" "unprognostic (1.01e-2)" "unprognostic (6.87e-3)" "unprognostic (1.18e-1)" "unprognostic (1.14e-4)" "unprognostic (7.94e-2)" "unprognostic (2.47e-1)" "unprognostic (1.84e-2)" "unprognostic (3.03e-2)" "unprognostic (4.97e-4)" "unprognostic (2.81e-1)" "unprognostic (1.14e-3)" "unprognostic (1.64e-2)" "unprognostic (1.15e-2)" "unprognostic (1.09e-2)" "unprognostic (3.75e-3)" 2.3 4.5 21.4 1.7 41.2 1.2 3.7 21.0 66.2 3.3 2.3 27.5 0.0 1.5 3.3 2.4 3.9 4.4 2.2 2.2 28.3 17.3 5.4 1.8 2.0 1.6 20.3 24.8 9.7 2.1 1.9 4.4 2.7 16.0 4.1 2.1 0.1 3.8 3.7 28.2 1.9 1.6 3.3 25.8 2.0 1.8 7.6 23.0 0.0 6.3 0.0 1.3 2.1 0.8 2.1 2.4 5.3 3.1 3.1 8.3 1.3 0.3 2.5 11.8 2.8 4.8 7.0 0.7 0.0 1.2 0.9 0.9 0.2 0.9 1.0 0.5 1.7 0.5 0.1 0.1 0.2 1.4 0.8 0.1 0.8 0.0 0.0 0.1 0.6 0.2 0.0 0.0 0.0 0.3 0.3 0.9 0.2 0.7 0.5 0.5 3.4 2.2 0.8 0.0 0.3 0.1 0.0 12.9 1.4 1.1 3.8 1.5 4.4 0.1 0.1 1.0 1.1 0.7 0.7 0.1 0.7 0.6 1.1 0.3 1.1 5.3 1.4 2.1 1.7 2.1 2.5 1.9 2.9 1.6 1.3 2.1 2.4 2.3 3.9 3.1 3.1 2.4 8.3 1.3 21.4 41.2 21.0 27.9 28.3 17.3 20.3 24.8 16.0 23.0 CACNG3 ENSG00000006116 "Calcium voltage-gated channel auxiliary subunit gamma 3" O60359 16 24255553-24362801 "Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 18 "brain: 32.2" "Cell line enhanced" "Detected in some" "HeLa: 1.3;Karpas-707: 1.0;U-266/70: 1.0" "Cancer enriched" "Detected in single" 15 "glioma: 0.7" "Group enriched" "Detected in many" 6 "amygdala: 12.8;basal ganglia: 13.1;cerebral cortex: 20.0;hippocampal formation: 12.7" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA077238 Enhanced "HPA077238: " "unprognostic (5.61e-2)" "unprognostic (3.09e-1)" "unprognostic (2.12e-1)" "unprognostic (1.17e-1)" 0.4 1.8 12.8 0.4 13.1 0.5 0.3 0.2 32.2 0.3 0.4 0.1 0.0 0.3 0.3 0.4 0.3 0.4 0.3 0.3 12.7 2.2 0.3 0.4 0.3 0.4 1.8 2.3 0.4 0.3 0.3 0.0 0.4 0.3 0.4 0.4 0.1 0.3 0.4 0.3 0.4 0.3 0.4 0.3 0.4 0.4 0.6 0.0 0.0 0.3 0.0 0.4 0.3 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 1.3 0.0 0.0 0.5 0.1 0.0 0.0 0.1 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 1.0 0.0 0.2 0.9 0.2 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 12.8 13.1 0.2 20.0 12.7 2.2 1.8 2.3 0.3 0.0 CALHM1 FAM26C ENSG00000185933 "Calcium homeostasis modulator 1" Q8IU99 10 103453387-103458888 "Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 5.7;kidney: 2.4;lymphoid tissue: 2.0" "Cell line enhanced" "Detected in some" "RPMI-8226: 4.1;U-266/70: 4.3;U-266/84: 4.9" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in single" HPA061816 Enhanced "HPA061816: " "unprognostic (2.46e-1)" "unprognostic (2.66e-1)" "unprognostic (2.38e-1)" "unprognostic (1.30e-1)" "unprognostic (5.65e-3)" "unprognostic (3.44e-2)" "unprognostic (2.86e-2)" "unprognostic (1.67e-2)" "unprognostic (2.51e-1)" "unprognostic (1.40e-1)" "unprognostic (3.44e-1)" "unprognostic (2.21e-8)" "unprognostic (1.96e-1)" "unprognostic (1.37e-1)" "unprognostic (1.06e-1)" "unprognostic (1.38e-2)" 0.0 0.0 1.1 0.5 0.3 0.8 0.0 3.4 5.7 0.0 0.0 0.5 0.1 0.3 0.0 0.0 0.4 0.1 1.2 2.5 2.4 0.0 0.0 0.4 1.3 0.1 0.4 0.0 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.3 0.2 0.0 0.2 0.3 0.1 0.2 0.0 2.0 0.2 0.0 1.0 1.6 0.8 1.6 1.3 1.0 0.2 0.4 0.3 0.3 0.4 0.1 0.0 0.5 0.3 0.1 0.1 0.2 0.0 0.2 0.3 0.2 0.0 0.4 0.0 0.3 0.3 0.4 0.7 0.3 0.9 0.2 0.0 0.0 0.4 0.2 0.2 0.1 0.4 0.0 0.2 1.1 0.3 0.5 0.0 0.8 0.4 0.5 0.4 0.3 4.1 0.3 0.5 0.6 0.3 0.2 1.0 0.1 0.0 0.0 1.0 0.4 0.3 0.2 0.4 4.3 4.9 0.6 0.5 1.1 0.1 0.6 0.6 0.4 1.0 1.6 0.2 0.5 0.4 1.0 1.6 1.0 0.4 0.9 0.8 1.3 1.4 0.3 0.3 0.2 CALY "CALCYON, DRD1IP, NSG3" ENSG00000130643 "Calcyon neuron specific vesicular protein" Q9NYX4 10 133324072-133336935 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Endocytosis "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 9 "adrenal gland: 26.5;brain: 98.9;pituitary gland: 47.7" "Cell line enhanced" "Detected in some" "SH-SY5Y: 2.7;U-266/70: 2.6" "Group enriched" "Detected in some" 14 "glioma: 1.7;pancreatic cancer: 7.7" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory CD8 T-cell: 1.3;naive CD4 T-cell: 1.0" "Lineage enriched" "Detected in single" 14 "T-cells: 1.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA042283 Enhanced "HPA042283: AB_10794417" "unprognostic (1.43e-2)" "unprognostic (7.84e-2)" "unprognostic (3.77e-3)" "unprognostic (1.41e-2)" "unprognostic (7.32e-2)" "unprognostic (9.81e-3)" "unprognostic (2.56e-1)" "unprognostic (7.48e-2)" "unprognostic (1.36e-1)" "unprognostic (1.18e-1)" "prognostic favourable (3.54e-4)" "unprognostic (1.23e-2)" "unprognostic (4.19e-10)" "unprognostic (8.04e-3)" "unprognostic (1.29e-1)" "unprognostic (3.60e-1)" "unprognostic (1.63e-1)" 1.8 26.5 27.1 2.7 57.4 1.8 1.8 12.7 67.1 1.7 2.6 3.6 0.0 5.0 1.7 1.9 1.8 2.0 1.8 1.7 31.8 98.9 1.7 1.7 1.9 2.0 25.1 39.8 1.7 6.3 1.7 47.7 1.7 33.9 1.8 2.4 0.7 2.1 2.0 1.7 1.9 3.8 2.1 14.3 1.9 4.1 4.3 4.8 0.0 1.9 0.0 1.9 1.7 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.6 0.1 0.8 0.3 0.0 0.0 0.0 0.3 0.6 0.6 0.0 0.0 0.0 0.0 0.5 0.5 0.0 0.1 0.3 0.0 0.0 0.3 0.0 0.1 0.0 0.8 1.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.1 1.0 0.0 1.1 0.0 0.0 0.3 0.0 0.0 0.4 0.1 0.0 0.0 0.0 2.7 0.0 0.0 0.9 0.1 0.0 0.0 0.0 0.3 0.0 0.1 2.6 0.0 0.0 0.3 0.2 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.3 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 27.1 57.4 12.7 45.9 31.8 98.9 25.1 39.8 33.9 4.8 CAMK2N1 CaMKIINalpha ENSG00000162545 "Calcium/calmodulin dependent protein kinase II inhibitor 1" Q7Z7J9 1 20482391-20486220 "Predicted intracellular proteins" "Protein kinase inhibitor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 128.2" "Cell line enhanced" "Detected in many" "AN3-CA: 49.9;CAPAN-2: 46.6;Hep G2: 37.6;SK-BR-3: 37.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "gdT-cell: 4.4" "Group enriched" "Detected in many" 15 "B-cells: 1.5;T-cells: 4.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA075200 Approved "HPA075200: " "unprognostic (1.67e-1)" "unprognostic (2.70e-3)" "unprognostic (9.71e-3)" "unprognostic (3.13e-1)" "unprognostic (6.89e-3)" "prognostic unfavourable (1.37e-7)" "prognostic unfavourable (5.49e-4)" "prognostic unfavourable (1.66e-4)" "unprognostic (4.77e-2)" "unprognostic (1.31e-1)" "unprognostic (7.48e-3)" "unprognostic (1.93e-2)" "unprognostic (1.40e-3)" "unprognostic (4.44e-2)" "unprognostic (1.19e-1)" "unprognostic (1.96e-2)" "unprognostic (1.31e-2)" 4.9 30.8 128.2 4.8 50.1 1.0 10.7 12.4 120.1 9.1 40.3 26.9 5.9 38.0 11.8 19.7 12.2 5.1 13.8 5.9 76.6 39.3 37.8 25.6 18.7 1.6 42.1 71.0 11.0 4.9 9.3 9.6 6.2 27.6 15.1 37.6 2.2 14.4 21.4 3.7 3.0 40.4 12.0 44.3 6.1 7.3 2.9 28.8 0.0 2.9 0.1 4.0 9.6 5.7 1.5 0.0 0.2 0.0 0.0 4.4 0.2 14.2 4.1 3.5 49.9 6.9 12.9 0.5 12.2 27.9 2.2 1.1 4.6 46.6 1.4 3.5 5.0 24.0 1.0 20.9 1.4 2.6 0.9 0.3 0.2 37.6 7.6 0.0 1.4 2.0 9.8 1.3 5.1 3.8 1.4 0.1 24.8 3.9 0.0 0.1 0.6 0.9 1.2 2.2 0.0 14.0 21.6 13.7 3.8 6.6 37.7 3.5 7.2 0.1 1.1 8.4 10.9 11.5 4.8 0.0 0.0 0.5 28.6 3.1 5.1 0.0 0.0 0.0 4.4 0.0 3.2 1.5 1.6 1.2 0.0 0.1 0.8 1.2 0.2 0.0 0.0 0.0 0.0 0.2 128.2 50.1 12.4 120.1 76.6 39.3 42.1 71.0 27.6 28.8 CAMK2N2 CaM-KIIN ENSG00000163888 "Calcium/calmodulin dependent protein kinase II inhibitor 2" Q96S95 3 184259213-184261463 "Predicted intracellular proteins" "Protein kinase inhibitor" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 12 "adrenal gland: 14.2;brain: 38.3;pancreas: 37.0;pituitary gland: 12.5" "Cell line enhanced" "Detected in many" "REH: 18.7;SCLC-21H: 19.6;U-138 MG: 20.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA050835, HPA075200" Approved Supported Nucleoplasm,Centrosome "Nucleoplasm, Centrosome" "HPA050835: , HPA075200: " "unprognostic (7.28e-2)" "prognostic favourable (9.77e-4)" "unprognostic (1.24e-1)" "unprognostic (4.69e-2)" "unprognostic (1.32e-1)" "unprognostic (6.09e-2)" "unprognostic (2.20e-1)" "unprognostic (1.29e-2)" "unprognostic (1.88e-1)" "unprognostic (4.21e-2)" "unprognostic (5.98e-2)" "unprognostic (9.72e-3)" "unprognostic (5.17e-9)" "unprognostic (3.47e-1)" "unprognostic (2.39e-1)" "unprognostic (1.07e-1)" "unprognostic (1.76e-3)" 1.3 14.2 22.2 1.3 9.6 1.1 1.3 29.7 38.3 1.3 1.3 3.2 0.0 1.4 1.2 1.2 1.2 1.3 1.3 1.2 12.3 32.7 1.3 1.7 1.2 1.2 18.0 8.2 1.1 37.0 2.0 12.5 1.3 25.1 1.4 1.3 1.1 1.2 1.4 1.1 1.2 1.4 1.4 9.3 1.2 1.7 1.3 4.5 0.0 1.3 0.0 1.2 1.2 0.0 0.0 0.5 0.0 0.2 0.0 0.3 0.0 11.1 0.2 1.4 0.6 0.4 0.4 1.0 0.3 4.1 2.6 2.7 0.4 0.5 0.4 2.7 0.2 1.4 0.7 0.4 1.5 9.1 0.4 0.3 0.2 0.4 0.1 0.2 1.4 0.3 0.6 0.4 1.9 0.0 0.0 3.3 0.4 5.9 0.1 0.1 7.9 3.6 18.7 5.4 1.5 0.6 2.1 19.6 4.2 1.8 0.5 0.1 6.0 0.1 0.0 20.4 8.9 1.9 3.3 2.2 3.3 2.7 4.7 1.1 1.7 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 22.2 9.6 29.7 38.3 12.3 32.7 18.0 8.2 25.1 4.5 CDH9 ENSG00000113100 "Cadherin 9" Q9ULB4 5 26880600-27121150 "Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 46.8" "Cell line enhanced" "Detected in some" "K-562: 9.2;NTERA-2: 13.6" "Not detected" "Not detected" "Group enriched" "Detected in many" 7 "amygdala: 46.8;basal ganglia: 24.6;cerebral cortex: 23.7;hippocampal formation: 15.9;olfactory region: 15.6" "Cell type enhanced" "Detected in some" "neutrophil: 8.3" "Group enriched" "Detected in many" 5 "B-cells: 4.1;granulocytes: 8.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA007167 Approved "HPA007167: AB_1078489" "unprognostic (1.49e-1)" "unprognostic (2.27e-4)" 0.7 0.5 46.8 1.0 24.6 2.8 0.7 0.5 23.7 0.5 0.8 0.0 0.0 0.6 0.9 1.2 0.7 0.5 0.7 0.5 15.9 3.5 10.5 0.5 0.6 1.6 1.2 15.6 0.6 1.1 1.0 0.5 0.8 1.5 1.0 1.2 0.0 0.5 0.1 0.5 1.9 1.5 0.8 0.6 0.8 0.9 3.7 2.6 0.0 1.9 0.0 1.7 0.5 0.5 4.1 0.9 8.3 1.1 0.1 0.8 1.1 2.4 0.9 0.5 0.8 0.4 0.0 1.6 0.0 0.9 0.3 0.6 0.0 0.9 1.3 0.3 0.3 0.3 0.1 0.5 0.0 0.1 0.2 0.5 0.7 2.5 0.0 0.0 1.5 0.6 0.7 0.0 0.0 0.2 9.2 2.3 0.0 1.5 0.8 0.5 13.6 0.5 0.3 0.3 0.4 0.5 0.5 3.1 0.3 0.0 0.4 0.4 0.5 0.9 1.7 0.1 0.8 0.8 0.3 2.7 1.0 4.3 1.0 1.0 0.8 1.3 0.2 0.4 0.2 0.7 0.6 4.1 0.4 0.2 0.1 2.5 0.3 0.5 8.3 0.1 1.1 0.9 0.8 1.1 46.8 24.6 0.5 23.7 15.9 3.5 1.2 15.6 1.5 2.6 CHI3L2 "YKL-39, YKL39" ENSG00000064886 "Chitinase 3 like 2" Q15782 1 111200771-111243440 "Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" Hydrolase "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 86.7;salivary gland: 47.2" "Cell line enhanced" "Detected in some" "ASC diff: 23.5;MOLT-4: 83.0;U-698: 18.5" "Cancer enriched" "Detected in many" 8 "glioma: 104.0" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 36.0" "Group enriched" "Detected in many" 4 "B-cells: 16.8;T-cells: 36.0" "Low region specificity" "Detected in all" HPA005443 Approved "Secreted to blood" 480000 "HPA005443: AB_1078510" "unprognostic (1.02e-2)" "unprognostic (4.34e-2)" "unprognostic (1.37e-1)" "unprognostic (4.16e-2)" "prognostic unfavourable (9.10e-5)" "prognostic favourable (2.19e-4)" "unprognostic (7.12e-2)" "unprognostic (1.39e-1)" "unprognostic (1.49e-3)" "unprognostic (1.26e-2)" "unprognostic (1.32e-2)" "unprognostic (2.44e-2)" "prognostic unfavourable (8.59e-7)" "unprognostic (7.15e-3)" "unprognostic (7.68e-2)" "unprognostic (1.39e-3)" "unprognostic (1.20e-1)" 8.3 0.9 3.9 38.7 11.9 0.9 13.4 0.3 11.9 0.7 2.5 5.9 0.3 0.4 0.6 3.7 2.2 0.7 4.4 20.8 8.3 8.3 3.0 0.3 21.0 19.1 5.6 1.2 1.4 0.3 0.1 1.6 5.8 7.3 3.9 1.0 4.2 47.2 0.3 3.0 3.2 2.6 1.2 28.4 18.4 2.5 4.4 2.1 86.7 4.2 4.2 39.4 19.3 1.7 16.8 0.5 0.9 1.2 6.4 36.0 10.1 0.0 0.0 0.1 0.1 23.5 4.1 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.8 0.0 0.0 6.8 0.0 0.0 0.1 0.3 0.3 0.0 0.4 5.6 0.0 0.1 0.1 0.0 0.0 0.3 0.0 0.0 83.0 0.1 0.0 0.0 0.4 0.2 0.2 0.0 0.1 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.1 1.8 0.3 0.0 0.1 1.3 0.1 18.5 5.8 0.1 0.5 0.3 1.2 0.1 8.7 0.3 2.2 14.3 6.1 14.3 0.3 16.8 36.0 13.6 0.9 6.4 0.2 0.5 3.6 10.1 3.9 11.9 0.3 5.4 8.3 8.3 5.6 1.2 7.3 2.1 CHRNA5 ENSG00000169684 "Cholinergic receptor nicotinic alpha 5 subunit" P30532 15 78565520-78595269 "Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "vagina: 33.9" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA054381 Approved Approved "Plasma membrane,Focal adhesion sites" "Focal adhesion sites" "Plasma membrane" "HPA054381: " "unprognostic (2.66e-1)" "unprognostic (1.76e-1)" "unprognostic (2.32e-2)" "unprognostic (3.20e-3)" "unprognostic (6.66e-2)" "unprognostic (1.29e-3)" "unprognostic (7.03e-5)" "prognostic unfavourable (3.64e-5)" "unprognostic (1.34e-2)" "unprognostic (1.31e-2)" "unprognostic (4.52e-2)" "unprognostic (8.97e-2)" "unprognostic (6.50e-11)" "unprognostic (4.37e-1)" "unprognostic (5.39e-1)" "unprognostic (5.44e-2)" "unprognostic (2.22e-1)" 2.9 3.3 1.7 4.4 1.7 0.6 4.9 1.8 1.7 2.7 6.4 0.4 1.6 7.8 4.7 1.9 4.0 1.1 16.3 2.4 1.7 1.8 0.9 1.8 1.4 2.0 1.9 0.3 1.7 11.8 0.0 0.7 2.1 1.2 3.6 7.1 3.5 1.7 0.7 5.8 1.0 6.8 6.1 1.3 1.9 5.3 9.8 0.6 4.5 1.6 2.9 4.4 5.7 33.9 0.9 1.1 3.4 1.6 1.6 1.4 0.7 6.6 17.1 9.3 5.2 1.1 0.8 3.8 4.9 2.4 5.4 9.9 6.5 31.6 3.9 12.1 1.0 5.9 17.9 7.2 5.6 8.0 21.4 7.3 13.4 6.5 0.6 4.9 10.4 0.3 1.3 1.4 2.0 10.1 7.1 5.2 3.4 14.5 6.2 1.7 7.5 4.7 8.0 10.8 4.0 6.5 15.9 15.8 23.2 11.7 11.4 5.4 25.4 1.2 2.2 7.4 8.9 5.4 15.3 6.0 24.7 4.4 4.5 8.0 6.8 3.0 1.6 2.5 0.8 1.6 0.4 0.3 0.8 0.5 0.9 0.9 1.4 1.4 3.4 1.6 1.3 1.1 0.3 0.7 1.7 1.7 1.8 1.7 1.7 1.8 1.9 0.3 1.2 0.6 CLVS1 "C6orf212L, CRALBPL, MGC34646, RLBP1L1" ENSG00000177182 "Clavesin 1" Q8IUQ0 8 61057158-61501645 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 33.8;pituitary gland: 10.3" "Cell line enhanced" "Detected in some" "SCLC-21H: 8.2;SH-SY5Y: 3.6;U-266/70: 3.6" "Cancer enhanced" "Detected in single" "glioma: 0.5" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA076650 Approved "HPA076650: " "unprognostic (1.86e-2)" "unprognostic (3.09e-4)" "unprognostic (2.79e-1)" "unprognostic (2.96e-7)" "unprognostic (1.11e-1)" "unprognostic (7.29e-2)" "unprognostic (2.99e-1)" "unprognostic (8.02e-4)" "unprognostic (2.23e-1)" "unprognostic (8.44e-3)" "unprognostic (7.25e-3)" "unprognostic (2.94e-1)" "unprognostic (5.79e-8)" "unprognostic (2.49e-1)" "unprognostic (3.19e-2)" "unprognostic (9.71e-2)" "unprognostic (1.14e-2)" 4.0 1.1 9.7 1.3 20.5 1.1 1.9 33.8 16.8 0.7 1.0 2.3 0.0 0.9 0.6 0.7 4.4 1.8 1.3 1.4 5.9 7.7 0.7 0.8 1.0 1.6 4.4 8.0 0.7 0.5 0.5 10.3 0.8 10.2 1.1 0.8 0.5 3.3 0.6 1.6 4.1 1.2 0.6 2.3 1.5 0.8 5.3 3.7 0.0 3.7 0.0 2.6 0.7 0.4 2.2 1.2 4.3 1.2 2.6 1.4 0.7 0.4 0.8 0.4 1.3 0.4 0.1 0.1 0.4 0.0 0.0 0.3 0.4 0.3 3.1 0.0 0.0 0.6 0.0 0.5 0.2 0.4 0.8 0.2 0.6 0.2 0.0 0.3 0.8 0.0 0.0 0.4 0.3 0.2 0.0 0.8 0.0 0.2 0.3 1.1 1.7 0.6 2.7 2.2 0.3 0.9 0.1 8.2 3.6 0.3 0.4 0.0 0.6 1.1 0.7 0.5 0.5 0.3 0.4 3.6 1.6 0.6 2.1 0.2 0.1 2.7 1.2 0.8 1.0 0.9 0.6 1.3 1.1 0.7 0.2 2.2 0.7 1.4 4.3 2.6 0.6 1.2 0.3 0.7 9.7 20.5 33.8 13.7 5.9 7.7 4.4 8.0 10.2 3.7 DCX "DBCN, DC, LISX, SCLH, XLIS" ENSG00000077279 Doublecortin O43602 X 111293779-111412429 "Disease related genes, Predicted intracellular proteins" "Differentiation, Neurogenesis" "Developmental protein" "Disease mutation, Epilepsy, Lissencephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 17.1;testis: 6.4" "Group enriched" "Detected in some" 8 "SCLC-21H: 33.8;SH-SY5Y: 13.9" "Cancer enriched" "Detected in some" 5 "glioma: 5.2" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in many" 9 "olfactory region: 90.9" "Region enriched" "Detected in all" 4 "olfactory region: 130.1" HPA036121 Enhanced Supported Approved Cytosol Cytosol "HPA036121: " "unprognostic (1.36e-2)" "unprognostic (1.99e-1)" "unprognostic (7.36e-2)" "unprognostic (4.00e-2)" "unprognostic (1.50e-1)" "unprognostic (2.24e-1)" "unprognostic (2.00e-2)" "unprognostic (7.18e-2)" "unprognostic (3.24e-2)" "unprognostic (2.33e-3)" "unprognostic (3.67e-1)" "unprognostic (4.90e-4)" "unprognostic (5.02e-3)" "unprognostic (1.27e-1)" "unprognostic (1.85e-1)" 0.8 1.1 7.0 0.7 9.2 0.7 3.2 0.7 17.1 0.7 0.6 0.9 0.0 0.7 4.1 3.6 0.6 0.6 0.8 0.7 4.2 5.4 0.5 0.5 0.6 0.7 2.5 6.7 0.6 0.8 0.5 1.0 0.6 3.7 0.5 0.8 0.0 2.2 0.6 0.5 0.7 0.7 0.6 3.0 0.6 1.2 6.4 2.3 0.0 0.6 0.0 0.5 0.6 0.3 0.3 0.4 0.6 0.2 0.7 0.4 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.5 0.0 0.0 0.0 33.8 13.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.2 0.2 0.2 0.1 0.4 0.3 0.3 0.2 0.1 0.3 0.3 0.3 0.6 0.7 0.0 0.4 0.1 0.0 7.0 9.2 0.7 10.8 4.2 5.4 2.5 6.7 3.7 2.3 DDX25 GRTH ENSG00000109832 "DEAD-box helicase 25" Q9UHL0 11 125903348-125943702 "Enzymes, Plasma proteins, Predicted intracellular proteins" "Differentiation, mRNA transport, Spermatogenesis, Translation regulation, Transport" "Developmental protein, Helicase, Hydrolase, RNA-binding" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "brain: 17.3;testis: 64.2" "Group enriched" "Detected in some" 4 "NTERA-2: 13.6;SCLC-21H: 11.0" "Cancer enhanced" "Detected in some" "glioma: 1.0" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 3.3" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA020137 Enhanced "HPA020137: AB_1847552" "unprognostic (5.78e-3)" "unprognostic (9.75e-3)" "unprognostic (7.93e-2)" "unprognostic (5.09e-3)" "unprognostic (1.11e-2)" "unprognostic (1.78e-2)" "unprognostic (1.54e-1)" "unprognostic (2.91e-3)" "unprognostic (6.24e-5)" "unprognostic (2.57e-1)" "unprognostic (2.44e-3)" "unprognostic (3.89e-1)" "unprognostic (3.44e-3)" "unprognostic (1.44e-1)" "unprognostic (1.76e-1)" "unprognostic (9.72e-2)" "unprognostic (1.69e-1)" 0.7 2.8 8.7 0.8 13.2 0.9 0.8 7.9 17.3 0.8 0.8 2.0 0.0 1.0 0.9 0.9 0.8 0.9 0.8 0.7 8.4 7.1 2.7 0.8 0.8 0.8 4.8 8.9 1.2 1.8 2.6 7.1 0.9 5.9 0.9 0.8 2.3 0.8 1.0 0.8 1.6 0.8 0.7 3.4 0.9 1.0 64.2 3.0 0.0 4.3 0.0 0.8 0.7 0.2 0.6 0.5 3.3 0.3 1.3 0.5 0.1 0.0 0.0 2.7 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.9 0.0 0.2 1.5 0.2 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.3 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.4 0.0 0.6 2.0 0.1 13.6 0.0 0.5 0.0 0.0 0.0 0.1 11.0 2.5 0.2 0.0 1.9 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.0 0.0 0.8 2.1 0.3 0.6 0.3 0.2 0.2 0.4 0.5 0.2 0.1 0.6 0.4 0.3 3.3 1.3 0.2 0.5 0.1 0.1 8.7 13.2 7.9 12.5 8.4 7.1 4.8 8.9 5.9 3.0 DNER "bet, UNQ26" ENSG00000187957 "Delta/notch like EGF repeat containing" Q8NFT8 2 229357629-229714558 "Cancer-related genes, Predicted membrane proteins" "Notch signaling pathway" "Activator, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "adrenal gland: 45.6;brain: 85.2;salivary gland: 46.1" "Group enriched" "Detected in some" 5 "hTERT-HME1: 39.4;U-138 MG: 66.4;U-87 MG: 39.3" "Cancer enriched" "Detected in many" 32 "glioma: 73.2" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "plasmacytoid DC: 1.4" "Lineage enhanced" "Detected in single" "dendritic cells: 1.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA017320 Enhanced 2700000 "HPA017320: AB_1847808" "unprognostic (4.39e-2)" "unprognostic (1.83e-1)" "unprognostic (3.25e-1)" "unprognostic (1.00e-3)" "unprognostic (8.73e-2)" "unprognostic (6.23e-2)" "prognostic unfavourable (1.05e-4)" "unprognostic (4.23e-3)" "unprognostic (2.97e-1)" "unprognostic (1.17e-1)" "unprognostic (1.60e-1)" "unprognostic (8.60e-2)" "prognostic unfavourable (3.42e-4)" "unprognostic (2.59e-2)" "unprognostic (7.32e-2)" "unprognostic (5.63e-2)" "unprognostic (5.13e-3)" 1.7 45.6 25.4 2.2 26.8 1.3 3.1 19.5 85.2 2.2 2.3 38.4 0.0 1.6 2.1 5.7 1.5 4.1 1.5 6.8 23.9 36.8 9.7 1.3 2.0 1.5 39.8 15.2 1.6 1.9 1.7 9.6 1.5 30.0 2.8 2.2 2.5 46.1 1.6 1.3 2.5 1.9 2.2 26.4 1.3 8.3 2.0 30.4 0.0 1.4 0.0 2.1 1.4 0.2 0.0 1.4 0.0 0.3 0.0 0.0 0.0 0.1 0.5 1.0 0.0 0.1 0.1 0.0 0.0 0.3 2.2 0.7 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.3 1.1 0.0 0.0 0.0 3.5 0.0 0.3 0.0 0.0 0.7 2.4 1.7 39.4 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.6 3.6 0.0 0.4 0.0 3.7 0.0 7.9 0.6 0.2 0.0 0.2 0.0 0.0 0.0 66.4 0.0 2.2 9.9 0.0 0.0 0.0 39.3 0.0 2.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.3 1.4 0.0 0.0 25.4 26.8 19.5 26.6 23.9 36.8 39.8 15.2 30.0 30.4 DOCK3 "KIAA0299, MOCA, PBP" ENSG00000088538 "Dedicator of cytokinesis 3" Q8IZD9 3 50675241-51384198 "Disease related genes, Predicted intracellular proteins" "Guanine-nucleotide releasing factor" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 38.9" "Cell line enhanced" "Detected in some" "AN3-CA: 8.0;HAP1: 5.4;HEK 293: 5.5;HMC-1: 6.4;U-87 MG: 10.6" "Cancer enhanced" "Detected in many" "thyroid cancer: 7.6" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA037543, HPA037544" Enhanced Enhanced Cytosol Cytosol "HPA037543: AB_10672495, HPA037544: AB_10670383" "unprognostic (1.02e-1)" "unprognostic (1.11e-1)" "unprognostic (1.78e-3)" "unprognostic (6.35e-8)" "unprognostic (2.63e-1)" "unprognostic (3.02e-2)" "unprognostic (4.64e-2)" "unprognostic (3.67e-1)" "unprognostic (1.91e-1)" "unprognostic (7.99e-2)" "unprognostic (2.36e-3)" "unprognostic (1.34e-2)" "unprognostic (1.45e-2)" "unprognostic (5.83e-5)" "unprognostic (7.96e-2)" "unprognostic (6.19e-2)" "unprognostic (1.24e-1)" 1.6 5.5 15.3 1.7 19.8 1.6 1.7 24.2 38.9 1.7 2.3 11.6 1.9 1.7 2.1 2.7 4.2 2.2 1.9 4.6 11.5 9.8 1.9 1.3 1.8 1.8 9.1 17.6 1.7 2.0 15.8 9.2 1.5 13.1 3.8 1.9 1.8 3.2 5.0 4.3 4.0 1.7 3.1 8.5 1.8 1.7 9.0 10.7 0.0 17.4 0.0 1.9 2.0 0.7 0.7 0.7 0.2 2.0 0.6 1.3 0.0 0.1 0.2 0.2 8.0 0.0 0.0 3.5 0.1 0.2 0.4 0.3 0.2 0.5 0.0 0.7 2.5 0.5 5.4 0.0 0.1 4.6 5.5 0.1 1.3 0.1 0.1 0.2 6.4 0.1 0.2 0.3 0.0 0.1 0.0 0.1 0.6 0.3 0.0 0.0 2.6 2.5 0.0 0.8 0.0 0.4 0.7 4.9 0.0 0.4 4.5 0.1 0.1 0.0 0.5 0.3 2.2 0.3 2.8 0.3 0.0 0.0 10.6 1.0 0.1 0.0 0.1 0.2 0.5 0.4 0.5 0.4 0.4 0.2 0.1 0.7 1.3 0.5 0.2 0.6 2.0 0.7 0.1 0.0 15.3 19.8 24.2 25.3 11.5 9.8 9.1 17.6 13.1 10.7 EGR4 "NGFI-C, PAT133" ENSG00000135625 "Early growth response 4" Q05215 2 73290929-73293705 "Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in some" 4 "brain: 20.0" "Cell line enriched" "Detected in some" 6 "HMC-1: 5.9" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA028983 Enhanced "HPA028983: AB_10603665" "unprognostic (7.75e-2)" "unprognostic (1.17e-1)" "unprognostic (1.39e-4)" "unprognostic (2.43e-3)" "unprognostic (2.68e-2)" "unprognostic (8.37e-2)" "unprognostic (1.75e-1)" "unprognostic (5.03e-2)" "unprognostic (5.20e-2)" "unprognostic (4.00e-1)" "unprognostic (2.29e-4)" "unprognostic (2.41e-1)" "unprognostic (1.75e-2)" "unprognostic (3.20e-2)" "unprognostic (1.77e-1)" "unprognostic (1.21e-2)" "unprognostic (4.07e-3)" 1.1 0.8 4.9 1.0 15.9 0.9 0.6 17.2 20.0 0.6 0.6 1.2 0.0 0.5 0.6 0.5 0.6 0.6 0.6 0.6 8.8 1.9 0.6 0.6 0.6 0.6 0.3 4.4 0.6 0.5 0.6 2.3 0.6 0.0 0.7 0.6 0.0 0.5 0.5 0.6 0.6 0.6 0.6 0.3 0.6 0.7 4.9 2.6 0.0 0.5 0.0 0.6 0.8 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 1.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 5.9 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.7 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.9 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 15.9 17.2 20.0 8.8 1.9 0.3 4.4 0.0 2.6 FGF2 FGFB ENSG00000138685 "Fibroblast growth factor 2" P09038 4 122826708-122898236 "Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins, Transporters" "Angiogenesis, Differentiation" "Developmental protein, Growth factor, Heparin-binding, Mitogen" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ: 56.5;BJ hTERT+: 33.1;fHDF/TERT166: 61.3;hTERT-HME1: 33.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000125, HPA065502" Enhanced Supported "Nucleoplasm,Nuclear bodies" "Secreted in other tissues" "Nucleoplasm, Nuclear bodies" "CAB000125: , HPA065502: " "unprognostic (1.53e-2)" "unprognostic (3.12e-1)" "unprognostic (1.08e-1)" "unprognostic (7.42e-2)" "unprognostic (2.10e-1)" "unprognostic (3.33e-1)" "unprognostic (6.98e-2)" "unprognostic (1.25e-1)" "unprognostic (2.82e-1)" "unprognostic (1.79e-1)" "prognostic unfavourable (9.85e-4)" "unprognostic (3.37e-1)" "unprognostic (4.61e-3)" "unprognostic (2.36e-1)" "unprognostic (1.81e-1)" "unprognostic (4.45e-2)" "unprognostic (3.45e-3)" 28.1 3.8 19.4 6.9 21.3 0.7 12.1 6.5 15.3 10.2 14.2 10.3 1.9 2.6 17.9 6.3 6.4 10.1 9.4 5.6 17.1 11.0 5.5 2.9 8.3 2.5 9.9 10.7 16.8 2.4 10.1 4.0 8.1 18.6 10.3 5.6 7.5 4.6 11.9 2.0 2.3 4.1 16.2 17.3 1.9 7.6 3.0 12.3 0.0 3.1 3.8 2.7 7.5 14.5 0.8 0.8 0.5 0.5 0.3 1.0 0.0 1.2 3.1 1.7 6.8 4.3 7.2 0.0 56.5 33.1 23.7 13.8 0.0 0.1 0.0 6.6 61.3 0.2 1.8 0.1 23.9 4.4 0.8 0.0 6.4 0.0 12.8 0.3 0.0 3.9 0.3 23.4 33.8 2.6 1.7 1.9 6.1 0.0 0.0 0.0 5.1 1.3 0.0 0.9 0.0 7.5 0.0 1.0 0.9 10.9 0.0 0.4 0.0 0.1 2.3 19.6 3.8 7.2 4.8 3.3 3.6 0.0 5.6 0.0 2.0 0.5 0.5 0.4 0.3 0.4 0.2 0.4 0.5 0.4 0.2 0.8 0.7 1.0 0.4 0.3 0.4 0.8 0.7 0.0 19.4 21.3 6.5 15.3 17.1 11.0 9.9 10.7 18.6 12.3 GPR26 ENSG00000154478 "G protein-coupled receptor 26" Q8NDV2 10 123666355-123694607 "G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 10 "brain: 8.6" "Cell line enriched" "Detected in single" 16 "SCLC-21H: 5.3" "Cancer enriched" "Detected in single" 13 "breast cancer: 0.7" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA062736 Enhanced "HPA062736: " "unprognostic (4.15e-2)" "unprognostic (5.75e-2)" "unprognostic (3.42e-1)" "unprognostic (2.12e-1)" "unprognostic (9.09e-2)" "unprognostic (9.98e-2)" "unprognostic (2.12e-2)" "unprognostic (1.16e-2)" "unprognostic (1.12e-1)" 0.0 0.0 1.0 0.1 0.2 0.1 0.0 0.0 8.6 0.0 0.4 0.0 0.0 0.0 0.1 0.0 0.1 0.1 2.6 2.4 0.0 0.3 0.0 0.1 4.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.2 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.2 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 5.3 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 GRIN1 "GluN1, NMDAR1" ENSG00000176884 "Glutamate ionotropic receptor NMDA type subunit 1" Q05586 9 137138390-137168762 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 38 "brain: 97.5" "Cell line enhanced" "Detected in some" "REH: 3.0;RPMI-8226: 4.3;SCLC-21H: 9.8;SH-SY5Y: 6.8" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA067773 Enhanced "HPA067773: " "unprognostic (3.58e-2)" "unprognostic (4.51e-1)" "unprognostic (2.68e-2)" "unprognostic (5.48e-4)" "unprognostic (5.20e-2)" "unprognostic (1.25e-1)" "unprognostic (2.34e-2)" "unprognostic (2.81e-2)" "unprognostic (6.46e-3)" "unprognostic (1.51e-1)" "unprognostic (1.69e-1)" "unprognostic (1.78e-1)" "unprognostic (1.21e-3)" "unprognostic (4.47e-2)" "unprognostic (1.44e-1)" "unprognostic (3.56e-3)" "unprognostic (4.72e-2)" 1.7 2.0 23.6 2.0 47.5 1.7 1.8 28.1 97.5 1.8 2.0 3.2 0.0 2.2 1.7 1.8 1.7 1.7 1.7 1.7 29.1 26.4 1.8 1.7 1.8 1.8 15.4 37.9 1.7 1.8 1.8 0.0 1.7 22.0 2.2 1.8 0.7 2.5 1.8 1.7 1.8 2.2 1.8 4.7 1.8 1.8 1.9 6.3 0.0 1.7 0.0 1.8 1.8 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.7 0.0 0.1 0.0 0.0 0.4 1.0 0.0 0.1 0.0 1.2 0.0 0.0 0.0 1.5 0.1 0.0 0.2 0.2 0.0 0.1 1.3 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.9 0.0 0.0 0.1 0.0 3.0 0.0 4.3 0.0 0.0 9.8 6.8 0.1 0.5 0.0 2.4 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 23.6 47.5 28.1 87.9 29.1 26.4 15.4 37.9 22.0 6.3 GRIN2D "EB11, GluN2D, NMDAR2D, NR2D" ENSG00000105464 "Glutamate ionotropic receptor NMDA type subunit 2D" O15399 19 48394875-48444931 "Disease related genes, FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 6.9" "Cell line enhanced" "Detected in many" "A549: 12.7;EFO-21: 8.8;HMC-1: 21.6;NB-4: 12.7;SK-BR-3: 11.3" "Low cancer specificity" "Detected in many" "Cell type enhanced" "Detected in single" "classical monocyte: 1.2" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB009006 Approved "CAB009006: AB_2279191" "unprognostic (9.96e-2)" "unprognostic (6.98e-2)" "unprognostic (1.17e-1)" "unprognostic (5.08e-3)" "unprognostic (1.46e-1)" "unprognostic (4.17e-1)" "unprognostic (1.43e-4)" "unprognostic (7.84e-2)" "unprognostic (2.72e-1)" "unprognostic (2.23e-3)" "unprognostic (1.57e-1)" "unprognostic (1.80e-1)" "unprognostic (6.66e-13)" "unprognostic (2.15e-2)" "unprognostic (1.92e-2)" "unprognostic (1.26e-3)" "unprognostic (1.14e-1)" 0.5 0.1 4.1 1.1 1.7 0.1 0.1 2.0 5.0 0.1 0.6 1.8 0.0 0.1 0.0 0.2 1.1 0.3 2.4 6.9 0.0 0.0 0.4 0.3 3.1 0.0 0.0 1.4 0.0 3.2 0.8 0.0 0.5 0.1 0.1 1.0 2.8 0.4 1.1 0.4 0.7 1.6 1.0 0.1 0.5 0.1 0.0 0.8 0.0 1.2 0.0 0.0 0.0 1.0 12.7 0.3 0.0 1.0 2.7 7.5 1.5 0.0 0.4 0.1 0.9 7.4 0.3 8.8 0.8 0.1 0.1 0.1 0.2 1.3 0.3 3.8 0.2 1.6 1.4 0.3 21.6 1.0 0.0 0.7 0.0 0.3 7.1 0.4 0.0 2.2 0.0 12.7 0.4 0.2 0.0 0.0 0.1 0.2 0.0 1.3 1.2 0.5 11.3 0.1 0.0 4.8 4.2 0.0 0.1 0.0 0.0 2.0 2.3 0.0 0.0 1.4 0.1 0.0 1.2 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 HAPLN4 "BRAL2, KIAA1926" ENSG00000187664 "Hyaluronan and proteoglycan link protein 4" Q86UW8 19 19255641-19262796 "Predicted secreted proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "brain: 38.5;intestine: 24.3" "Cell line enhanced" "Detected in some" "NB-4: 5.6;NTERA-2: 14.6;SCLC-21H: 3.1" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA055856 Enhanced "Secreted in brain" "HPA055856: " "unprognostic (3.36e-4)" 0.5 1.9 3.0 0.4 7.5 0.4 0.7 8.9 38.5 2.4 0.6 1.6 0.0 19.6 1.6 0.5 0.4 0.7 0.6 0.5 8.9 9.4 0.5 7.5 0.6 0.4 7.8 2.7 1.4 1.3 0.4 0.2 0.7 26.4 1.1 0.6 0.4 0.5 0.8 0.4 0.4 24.3 0.6 3.8 0.4 0.8 0.5 0.0 0.0 0.4 0.0 0.4 0.5 0.3 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.7 0.0 0.0 1.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.6 0.0 0.1 0.0 0.1 0.0 0.0 0.2 0.0 0.3 0.0 0.0 5.6 14.6 0.0 0.0 0.0 0.0 0.0 0.0 3.1 1.5 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 7.5 8.9 38.5 8.9 9.4 7.8 2.7 26.4 0.0 HCN4 ENSG00000138622 "Hyperpolarization activated cyclic nucleotide gated potassium channel 4" Q9Y3Q4 15 73319859-73369264 "Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Sodium transport, Transport" "Ion channel, Ligand-gated ion channel, Potassium channel, Sodium channel, Voltage-gated channel" "Brugada syndrome, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "brain: 4.3;heart muscle: 12.5;testis: 9.6" "Cell line enhanced" "Detected in some" "AF22: 2.5;CACO-2: 3.1;HDLM-2: 2.1;NTERA-2: 9.4;U-2 OS: 4.1" "Group enriched" "Detected in some" 8 "testis cancer: 3.1;thyroid cancer: 0.7" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA073174 Approved "HPA073174: " "unprognostic (2.21e-1)" "unprognostic (1.39e-1)" "unprognostic (2.18e-2)" "unprognostic (3.14e-2)" "unprognostic (5.30e-3)" "unprognostic (1.92e-2)" "unprognostic (2.19e-1)" "unprognostic (3.50e-2)" "unprognostic (2.37e-1)" "unprognostic (6.56e-2)" "unprognostic (1.13e-3)" "unprognostic (1.13e-1)" "unprognostic (6.05e-5)" "unprognostic (5.56e-2)" "unprognostic (4.60e-2)" "unprognostic (1.51e-2)" "unprognostic (7.95e-2)" 0.2 1.3 4.3 0.2 1.1 0.1 0.1 0.9 3.4 0.2 0.4 2.1 0.0 1.2 0.1 0.2 0.1 0.3 0.2 12.5 0.6 2.0 0.4 0.1 0.3 0.1 1.8 0.9 0.1 0.2 0.1 2.1 0.1 3.9 0.6 0.3 0.2 0.1 1.0 0.1 0.2 0.4 0.2 0.7 0.1 0.6 9.6 1.9 0.0 0.3 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.2 0.0 1.5 0.0 0.2 0.0 0.0 0.1 2.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 9.4 0.0 0.0 0.0 0.0 0.3 0.0 1.1 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 1.1 0.9 3.4 0.6 2.0 1.8 0.9 3.9 1.9 HTR7 5-HT7 ENSG00000148680 "5-hydroxytryptamine receptor 7" P34969 10 90740823-90857698 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, RAS pathway related proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "parathyroid gland: 30.8;testis: 14.3" "Cell line enhanced" "Detected in some" "HBEC3-KT: 8.1;hTCEpi: 7.3;hTERT-HME1: 24.5;LHCN-M2: 9.8;U-87 MG: 7.5;WM-115: 9.3" "Group enriched" "Detected in some" 5 "cervical cancer: 0.9;head and neck cancer: 3.3;lung cancer: 0.9;urothelial cancer: 1.3" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 12 "myeloid DC: 4.6" "Lineage enriched" "Detected in single" 12 "dendritic cells: 4.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB022708, HPA073617" Approved Supported "Nuclear speckles,Plasma membrane,Cytosol" "Plasma membrane" "Nuclear speckles, Cytosol" "CAB022708: , HPA073617: " "unprognostic (1.17e-1)" "unprognostic (1.24e-2)" "unprognostic (4.72e-2)" "unprognostic (1.33e-1)" "unprognostic (5.51e-3)" "unprognostic (1.71e-2)" "unprognostic (1.89e-1)" "unprognostic (1.44e-1)" "unprognostic (1.15e-1)" "unprognostic (4.58e-3)" "unprognostic (3.32e-1)" "unprognostic (1.45e-1)" "unprognostic (2.89e-1)" "unprognostic (1.23e-3)" "unprognostic (1.38e-1)" "unprognostic (1.84e-2)" "unprognostic (6.49e-2)" 1.0 0.5 2.4 1.1 2.5 0.5 0.7 0.3 4.3 0.6 0.8 1.7 1.2 0.8 0.4 0.3 1.0 0.4 1.3 0.6 9.9 5.1 0.3 0.6 0.5 0.7 1.7 1.8 0.4 1.4 30.8 0.2 0.5 3.1 1.0 1.2 0.4 0.6 0.3 1.7 0.9 2.2 3.6 1.5 1.3 1.5 14.3 1.0 0.0 0.3 0.1 0.6 3.5 2.1 0.0 4.6 0.0 0.3 0.0 0.2 0.1 0.2 0.0 0.0 0.0 0.1 0.7 0.0 0.5 0.2 0.5 0.7 0.0 0.9 0.0 0.0 0.1 3.3 0.9 8.1 2.0 0.0 0.1 0.0 0.0 0.0 3.8 0.0 0.4 5.8 7.3 2.4 24.5 0.0 0.0 0.0 9.8 0.0 0.0 0.1 0.9 1.2 0.7 0.1 0.0 0.0 0.9 0.3 0.0 0.3 0.0 3.8 0.0 0.2 0.2 4.5 0.0 0.0 6.8 0.0 0.0 0.0 7.5 0.0 9.3 0.0 0.1 0.0 0.1 0.2 0.0 0.0 0.1 0.1 4.6 0.0 0.2 0.2 0.0 0.0 0.3 0.0 0.1 0.1 2.4 2.5 0.3 4.3 9.9 5.1 1.7 1.8 3.1 1.0 KCNH8 "elk3, Kv12.1" ENSG00000183960 "Potassium voltage-gated channel subfamily H member 8" Q96L42 3 19148454-19535646 "Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "brain: 31.3;pituitary gland: 16.1" "Cell line enriched" "Detected in some" 4 "SH-SY5Y: 9.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory B-cell: 2.1;naive B-cell: 4.5" "Lineage enriched" "Detected in single" 5 "B-cells: 4.5" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA016586, HPA077537, HPA077773" Approved Supported "Plasma membrane" "Plasma membrane" "HPA016586: AB_1852127, HPA077537: , HPA077773: " "unprognostic (6.68e-3)" "unprognostic (1.68e-1)" "unprognostic (2.99e-2)" "unprognostic (8.56e-6)" "unprognostic (1.04e-1)" "unprognostic (1.10e-1)" "unprognostic (1.88e-1)" "unprognostic (9.13e-3)" "unprognostic (4.86e-2)" "unprognostic (1.69e-1)" "unprognostic (5.04e-3)" "unprognostic (2.90e-2)" "unprognostic (1.63e-1)" "unprognostic (1.17e-1)" "unprognostic (3.89e-2)" "unprognostic (8.71e-5)" "unprognostic (1.72e-1)" 0.6 7.0 8.4 1.6 22.0 1.4 2.4 1.3 11.4 1.3 1.9 31.3 0.0 2.2 1.2 1.2 0.7 1.4 2.2 1.0 11.8 5.7 0.7 0.7 0.8 3.2 16.4 10.2 0.7 2.7 0.8 16.1 0.6 15.0 2.2 2.5 0.1 3.3 1.4 0.6 1.9 1.8 1.1 9.9 2.6 5.9 4.0 18.1 0.0 1.1 0.0 3.2 0.9 0.5 4.5 0.9 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 1.1 9.5 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.2 0.0 0.0 1.1 0.2 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 4.5 0.3 0.0 0.0 0.0 0.0 0.9 0.0 0.0 8.4 22.0 1.3 11.4 11.8 5.7 16.4 10.2 15.0 18.1 KCNJ10 "Kir1.2, Kir4.1" ENSG00000177807 "Potassium voltage-gated channel subfamily J member 10" P78508 1 159998651-160070483 "Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "Deafness, Disease mutation, Epilepsy, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "brain: 74.1;kidney: 28.1" "Cell line enhanced" "Detected in some" "Hep G2: 11.4;SK-MEL-30: 3.6;U-266/70: 3.7" "Cancer enriched" "Detected in some" 6 "glioma: 27.4" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "T-reg: 2.5" "Group enriched" "Detected in many" 6 "NK-cells: 1.7;T-cells: 2.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA078302 Enhanced "HPA078302: " "unprognostic (2.64e-2)" "unprognostic (3.54e-3)" "unprognostic (6.19e-2)" "unprognostic (1.33e-1)" "unprognostic (2.84e-1)" "unprognostic (6.98e-4)" "unprognostic (1.96e-1)" "unprognostic (7.13e-2)" "unprognostic (3.43e-1)" "unprognostic (1.28e-3)" "unprognostic (5.80e-4)" "unprognostic (9.52e-2)" "unprognostic (2.09e-2)" "unprognostic (2.08e-2)" "unprognostic (1.41e-1)" "unprognostic (3.77e-1)" "unprognostic (6.70e-3)" 1.4 1.5 23.6 3.0 28.1 1.3 1.3 10.5 74.1 1.4 1.7 37.9 0.0 1.5 1.3 1.3 1.4 1.3 1.3 1.3 21.8 13.2 28.1 3.1 1.3 7.1 28.1 15.1 1.3 1.3 1.3 0.3 1.3 25.5 1.3 1.5 0.5 1.5 1.5 1.2 1.6 1.7 1.3 42.9 10.3 2.0 1.8 25.5 0.0 1.5 0.0 2.9 1.5 0.1 0.0 0.0 0.0 0.3 1.7 2.5 0.2 0.0 0.0 0.1 0.0 0.0 0.4 0.3 0.0 0.0 0.3 0.3 0.0 0.2 1.7 0.2 0.0 0.4 0.3 0.0 0.2 0.0 0.2 0.1 0.1 11.4 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.6 0.0 2.1 0.1 0.0 0.0 0.2 0.4 0.0 0.3 3.6 0.1 0.5 0.1 0.1 0.3 0.9 0.0 3.7 1.7 0.0 0.2 0.2 1.7 0.0 0.3 0.0 0.4 0.3 0.0 0.0 0.1 0.5 0.0 0.0 0.0 1.8 0.0 1.7 0.3 0.0 2.5 0.2 23.6 28.1 10.5 22.2 21.8 13.2 28.1 15.1 25.5 25.5 KIAA0319 NMIG ENSG00000137261 KIAA0319 Q5VV43 6 24544104-24646155 "Disease related genes, Predicted membrane proteins, Predicted secreted proteins" Neurogenesis "Developmental protein" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 23.5" "Cell line enhanced" "Detected in some" "A-431: 3.6;A549: 4.1;HDLM-2: 4.8;SCLC-21H: 7.8;U-266/84: 6.3" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 9 "memory B-cell: 1.4;neutrophil: 5.0" "Group enriched" "Detected in many" 32 "B-cells: 1.4;granulocytes: 5.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA015607, HPA076313" Enhanced Supported Approved Vesicles "Secreted in brain" Vesicles "HPA015607: AB_1852299, HPA076313: " "unprognostic (1.64e-1)" "unprognostic (2.81e-2)" "unprognostic (1.21e-1)" "unprognostic (1.31e-1)" "unprognostic (1.08e-1)" "unprognostic (1.77e-1)" "unprognostic (1.72e-2)" "unprognostic (4.65e-2)" "unprognostic (9.70e-2)" "unprognostic (2.21e-5)" "unprognostic (7.88e-4)" "unprognostic (9.53e-4)" "unprognostic (1.44e-6)" "unprognostic (1.20e-1)" "unprognostic (6.97e-2)" "unprognostic (3.13e-1)" "unprognostic (3.41e-2)" 0.9 1.9 9.9 1.3 10.2 0.9 1.1 10.7 23.5 0.9 1.6 4.0 0.0 0.9 0.9 0.9 0.8 4.8 1.4 0.8 9.7 7.7 0.9 0.8 2.2 0.9 5.8 12.1 0.8 3.0 0.8 3.8 1.1 10.2 1.7 1.7 0.0 0.8 0.9 0.8 2.4 1.1 1.1 1.4 1.1 3.2 3.5 2.3 0.0 0.8 0.0 1.1 0.9 0.1 1.4 0.0 5.0 0.0 0.0 0.0 0.0 3.6 4.1 0.2 2.6 0.0 0.0 0.1 0.0 0.1 0.1 0.3 0.2 1.5 1.1 2.0 0.0 1.7 0.7 0.0 0.0 4.8 1.8 0.0 3.5 0.2 0.0 0.0 0.9 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.0 1.2 0.1 0.0 0.5 0.3 0.2 0.0 0.8 0.1 0.2 7.8 0.5 0.1 2.2 0.0 0.8 0.0 0.0 0.0 0.6 0.4 0.7 0.6 6.3 0.3 1.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.3 0.0 0.0 5.0 0.0 0.0 0.0 0.0 0.0 9.9 10.2 10.7 14.9 9.7 7.7 5.8 12.1 10.2 2.3 KIF5A "D12S1889, MY050, NKHC, SPG10" ENSG00000155980 "Kinesin family member 5A" Q12840 12 57549998-57586632 "Disease related genes, Predicted intracellular proteins" "Motor protein" "Amyotrophic lateral sclerosis, Disease mutation, Epilepsy, Hereditary spastic paraplegia, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 18 "brain: 138.6" "Cell line enhanced" "Detected in some" "HDLM-2: 20.0;K-562: 8.4;NTERA-2: 10.3;SCLC-21H: 21.3;U-87 MG: 7.9" "Cancer enriched" "Detected in some" 5 "glioma: 26.4" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "MAIT T-cell: 1.4;naive CD8 T-cell: 2.0" "Lineage enriched" "Detected in single" 20 "T-cells: 2.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004469, HPA073448" Enhanced Approved "Nucleoplasm,Mitotic spindle,Cytosol" "Nucleoplasm, Cytosol" "Mitotic spindle" "HPA004469: AB_1079212, HPA073448: " "unprognostic (7.94e-2)" "unprognostic (4.95e-3)" "unprognostic (3.87e-1)" "unprognostic (3.34e-3)" "unprognostic (7.12e-2)" "unprognostic (4.22e-2)" "unprognostic (3.22e-5)" "unprognostic (2.82e-1)" "unprognostic (2.01e-1)" "unprognostic (1.52e-2)" "prognostic favourable (5.23e-4)" "unprognostic (7.61e-2)" "unprognostic (2.26e-4)" "unprognostic (4.75e-2)" "unprognostic (1.46e-1)" "unprognostic (4.12e-1)" "unprognostic (1.51e-1)" 1.8 7.6 85.4 3.0 47.6 1.9 1.9 15.2 138.6 2.1 2.8 4.0 0.0 2.4 3.4 2.1 1.9 2.0 1.9 1.7 52.4 18.3 2.0 1.7 1.8 1.8 12.9 43.6 1.8 2.3 6.0 2.5 1.7 21.6 1.9 2.8 0.6 2.0 2.0 1.7 1.7 3.0 2.8 9.0 1.8 2.1 4.4 12.9 0.0 2.8 0.0 1.8 1.8 0.2 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 3.7 3.2 0.0 0.0 0.1 0.2 0.7 1.3 1.7 0.0 0.0 1.6 0.0 0.6 0.1 2.0 0.0 1.0 20.0 1.4 0.1 0.1 1.6 0.6 0.0 0.1 0.2 0.1 1.0 0.0 0.2 8.4 4.4 0.0 0.0 0.3 0.0 10.3 0.0 0.0 0.0 0.0 0.2 0.0 21.3 4.8 0.0 0.2 0.0 0.4 0.0 0.0 0.0 2.4 0.0 0.9 2.8 3.4 0.3 7.9 0.0 0.1 0.0 0.0 0.0 0.4 0.0 1.4 0.0 0.4 0.8 0.0 0.0 0.8 2.0 0.0 0.0 0.0 0.0 0.3 0.0 85.4 47.6 15.2 112.0 52.4 18.3 12.9 43.6 21.6 12.9 KSR2 FLJ25965 ENSG00000171435 "Kinase suppressor of ras 2" Q6VAB6 12 117453012-117968983 "Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "brain: 27.4;pituitary gland: 24.6" "Group enriched" "Detected in some" 5 "HUVEC TERT2: 7.2;SCLC-21H: 5.3;TIME: 10.8" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA035536 Enhanced "HPA035536: AB_10673485" "unprognostic (1.74e-2)" "unprognostic (4.21e-2)" "unprognostic (2.38e-1)" "unprognostic (2.29e-2)" "unprognostic (9.11e-2)" "unprognostic (8.42e-2)" "unprognostic (6.91e-3)" "unprognostic (1.10e-2)" "unprognostic (5.78e-2)" "unprognostic (5.80e-2)" "unprognostic (2.05e-4)" "unprognostic (1.19e-1)" "unprognostic (9.28e-3)" "unprognostic (5.02e-2)" "unprognostic (5.68e-2)" "unprognostic (8.14e-3)" "unprognostic (5.74e-2)" 0.9 5.0 13.2 1.1 13.8 1.1 1.7 27.4 17.2 1.0 1.9 1.3 2.2 1.0 0.8 2.6 0.9 1.7 1.0 0.8 12.9 4.8 3.5 0.8 1.2 1.6 2.2 10.8 0.8 3.0 0.9 24.6 0.9 7.7 1.3 2.3 0.2 1.2 3.4 0.9 1.0 1.0 0.9 2.9 1.0 1.7 3.2 3.0 0.0 3.8 0.0 1.5 2.3 0.5 0.1 0.2 0.8 0.1 0.2 0.1 0.0 0.1 0.7 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.1 1.1 0.0 0.2 0.0 0.0 0.0 0.5 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.2 0.0 0.0 0.0 1.5 0.1 0.0 0.5 1.2 0.0 0.0 0.1 0.7 1.4 5.3 0.1 0.0 0.0 0.0 1.1 0.0 10.8 0.0 0.8 0.0 0.2 0.9 1.5 0.0 0.4 0.0 0.1 0.5 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.8 0.2 0.1 0.2 0.0 0.0 13.2 13.8 27.4 17.2 12.9 4.8 2.2 10.8 7.7 3.0 LINGO1 "FLJ14594, LERN1, LRRN6A" ENSG00000169783 "Leucine rich repeat and Ig domain containing 1" Q96FE5 15 77613027-77820900 "Predicted intracellular proteins, Predicted membrane proteins" "Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 7 "brain: 67.2" "Cell line enhanced" "Detected in some" "AF22: 13.2;AN3-CA: 11.0;HAP1: 16.6;HEK 293: 11.7;MCF7: 7.1;NTERA-2: 31.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA074653 Enhanced Approved "Plasma membrane" 8400 "Plasma membrane" "HPA074653: " "unprognostic (1.06e-1)" "unprognostic (7.07e-2)" "unprognostic (2.16e-2)" "unprognostic (1.48e-2)" "unprognostic (3.09e-1)" "unprognostic (2.20e-1)" "unprognostic (2.84e-2)" "unprognostic (3.77e-2)" "unprognostic (3.40e-1)" "unprognostic (1.10e-1)" "unprognostic (7.36e-2)" "unprognostic (2.74e-2)" "prognostic unfavourable (3.23e-7)" "unprognostic (2.07e-1)" "unprognostic (7.06e-2)" "unprognostic (2.85e-1)" "unprognostic (2.59e-2)" 3.0 1.6 27.4 1.7 21.8 0.8 1.3 9.1 67.2 3.8 2.0 5.9 0.0 2.0 3.3 2.7 1.4 3.1 2.5 9.7 29.8 12.2 2.2 1.1 1.1 1.3 10.3 21.8 1.7 2.7 1.1 0.5 6.1 6.8 1.7 1.5 1.8 3.4 2.5 1.0 3.0 1.5 4.5 6.8 3.3 2.0 3.7 3.9 0.0 1.7 0.0 1.1 3.2 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 13.2 11.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.8 0.0 0.0 16.6 0.0 0.0 0.0 11.7 0.0 0.0 0.2 0.2 0.0 0.0 0.1 0.3 0.0 0.0 0.0 1.7 0.1 0.0 7.1 0.0 0.0 31.3 0.0 0.0 0.0 0.2 0.0 0.0 2.4 0.7 0.0 1.3 2.8 0.2 0.2 1.1 0.0 2.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 27.4 21.8 9.1 47.5 29.8 12.2 10.3 21.8 6.8 3.9 LMTK3 "KIAA1883, LMR3, PPP1R101, TYKLM3" ENSG00000142235 "Lemur tyrosine kinase 3" Q96Q04 19 48485271-48513189 "Enzymes, Predicted membrane proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 38.1" "Cell line enhanced" "Detected in many" "HMC-1: 8.4;SK-BR-3: 10.0;U-266/70: 9.3;U-266/84: 7.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA040203, HPA077070" Enhanced Approved "Nucleoplasm,Cell Junctions" Nucleoplasm "Cell Junctions" "HPA040203: AB_10671690, HPA077070: " "unprognostic (2.41e-1)" "unprognostic (1.48e-1)" "unprognostic (5.37e-2)" "unprognostic (5.45e-2)" "unprognostic (2.95e-1)" "unprognostic (1.71e-2)" "unprognostic (5.67e-2)" "unprognostic (2.46e-1)" "unprognostic (2.09e-1)" "unprognostic (2.51e-3)" "unprognostic (5.71e-2)" "unprognostic (1.47e-1)" "prognostic favourable (3.18e-8)" "unprognostic (1.38e-1)" "unprognostic (3.22e-2)" "unprognostic (3.24e-1)" "unprognostic (6.11e-2)" 1.3 4.4 19.8 2.3 28.6 2.0 2.0 20.0 38.1 2.0 1.5 6.0 0.2 6.2 1.4 1.5 2.3 1.6 1.9 1.7 17.2 11.1 2.5 1.3 3.2 2.2 6.5 23.8 1.3 2.1 8.5 6.1 2.1 12.5 3.5 1.2 1.6 5.2 3.1 1.2 2.4 4.0 1.2 6.6 1.8 2.9 1.5 10.3 0.0 2.3 0.0 2.2 1.6 1.2 0.0 0.0 0.0 0.2 0.0 0.4 0.1 4.5 3.0 0.3 0.0 0.0 0.0 4.4 0.0 0.2 0.0 0.1 2.2 3.6 1.6 1.2 0.0 2.1 0.3 1.6 0.0 0.0 1.2 0.2 0.3 0.7 0.0 0.0 8.4 0.2 0.9 0.0 0.0 0.1 1.4 2.8 0.0 3.0 0.6 0.8 1.1 0.9 3.8 0.0 1.3 1.1 0.7 0.7 2.8 0.1 10.0 0.0 3.8 0.2 0.1 0.0 0.8 0.1 0.0 9.3 7.5 0.4 0.2 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.1 19.8 28.6 20.0 38.1 17.2 11.1 6.5 23.8 12.5 10.3 LRRC4C "KIAA1580, NGL-1" ENSG00000148948 "Leucine rich repeat containing 4C" Q9HCJ2 11 40114203-41459773 "Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 31.5" "Group enriched" "Detected in some" 6 "AF22: 16.9;U-2 OS: 18.6" "Cancer enhanced" "Detected in some" "glioma: 3.6" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 18 "naive B-cell: 1.7" "Lineage enriched" "Detected in single" 18 "B-cells: 1.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA054800, HPA075816" Approved Approved Cytosol Cytosol "HPA054800: , HPA075816: " "unprognostic (4.86e-3)" "unprognostic (3.43e-2)" "unprognostic (7.62e-3)" "unprognostic (4.87e-3)" "unprognostic (6.48e-2)" "unprognostic (1.42e-1)" "unprognostic (2.84e-1)" "unprognostic (4.64e-2)" "unprognostic (1.93e-1)" "unprognostic (2.22e-1)" "unprognostic (2.44e-1)" "unprognostic (1.49e-1)" "unprognostic (4.90e-13)" "unprognostic (5.05e-4)" "unprognostic (5.21e-1)" "unprognostic (1.12e-1)" "unprognostic (6.45e-3)" 1.6 5.7 20.2 1.6 23.7 0.5 2.6 3.6 31.5 5.3 1.9 3.3 0.0 1.1 2.3 1.0 1.2 1.3 1.8 2.6 16.7 8.7 0.9 2.1 1.6 1.4 7.5 10.3 1.6 1.0 4.3 3.2 0.5 8.7 1.5 1.6 1.3 1.4 3.0 0.7 0.7 1.3 2.4 6.0 1.3 0.9 0.9 7.9 0.0 4.0 0.0 1.6 1.1 1.7 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.5 18.6 0.0 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 20.2 23.7 3.6 16.4 16.7 8.7 7.5 10.3 8.7 7.9 MAP6D1 "FLJ12748, SL21" ENSG00000180834 "MAP6 domain containing 1" Q9H9H5 3 183815876-183825594 "Predicted intracellular proteins" Calmodulin-binding "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "brain: 48.1;skeletal muscle: 33.5" "Cell line enriched" "Detected in many" 5 "T-47d: 38.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "memory CD8 T-cell: 2.7" "Lineage enriched" "Detected in single" 5 "T-cells: 2.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA037991 Enhanced Supported Approved Cytosol Cytosol "HPA037991: AB_10672503" "unprognostic (9.23e-3)" "unprognostic (2.70e-1)" "unprognostic (1.65e-1)" "unprognostic (1.27e-3)" "unprognostic (1.32e-1)" "unprognostic (3.67e-2)" "unprognostic (1.21e-1)" "unprognostic (1.13e-1)" "unprognostic (2.42e-1)" "unprognostic (1.28e-2)" "unprognostic (5.36e-2)" "prognostic unfavourable (3.37e-4)" "unprognostic (8.81e-12)" "unprognostic (1.08e-1)" "unprognostic (2.96e-3)" "unprognostic (1.86e-1)" "unprognostic (5.72e-2)" 1.1 1.2 11.8 1.5 16.0 1.1 2.0 30.9 32.1 1.5 1.4 48.1 0.0 1.9 1.4 2.0 1.1 1.5 1.3 1.9 18.8 9.2 1.2 1.3 1.4 1.7 24.7 8.7 1.7 6.0 1.8 0.5 1.3 18.4 2.7 1.4 0.0 1.6 2.0 33.5 4.6 1.5 1.4 37.7 1.5 1.2 1.3 20.4 2.2 1.1 0.0 1.4 1.1 0.2 0.5 0.3 0.2 0.2 0.0 2.7 0.3 1.8 1.3 2.1 0.4 0.5 0.7 1.6 2.3 0.4 4.5 3.0 1.8 0.1 0.2 3.0 3.5 1.4 4.4 1.1 3.0 1.3 6.6 0.2 0.0 0.0 1.3 2.4 0.8 0.3 0.3 1.1 0.4 0.9 0.3 0.0 0.6 8.2 5.7 3.3 2.0 3.8 2.8 3.3 0.0 0.2 0.0 7.0 1.3 1.7 1.3 2.4 38.9 2.3 0.4 1.0 1.6 1.6 3.5 1.4 0.8 1.1 0.3 0.4 0.2 0.0 0.2 0.2 0.0 0.0 0.0 0.5 0.5 2.7 0.3 0.0 0.0 0.9 0.0 0.0 0.1 0.2 0.0 0.3 11.8 16.0 30.9 19.9 18.8 9.2 24.7 8.7 18.4 20.4 MYBPC1 ENSG00000196091 "Myosin binding protein C, slow type" Q00872 12 101568353-101686018 "Disease related genes, Predicted intracellular proteins" "Cell adhesion" "Actin-binding, Muscle protein" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "skeletal muscle: 739.9" "Cell line enhanced" "Detected in some" "AF22: 2.5;HSkMC: 3.3;SCLC-21H: 1.0" "Cancer enhanced" "Detected in many" "prostate cancer: 33.0" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 14 "intermediate monocyte: 1.4" "Lineage enriched" "Detected in single" 14 "monocytes: 1.4" "Group enriched" "Detected in some" 9 "cerebellum: 41.6;olfactory region: 12.2" "Low region specificity" "Detected in all" "HPA021004, HPA027614" Enhanced "HPA021004: AB_1854232, HPA027614: AB_10602711" "prognostic favourable (4.76e-5)" "unprognostic (7.72e-2)" "unprognostic (1.09e-1)" "unprognostic (1.81e-2)" "unprognostic (3.33e-2)" "unprognostic (4.63e-2)" "unprognostic (8.67e-2)" "unprognostic (2.93e-1)" "unprognostic (9.98e-3)" "unprognostic (2.56e-1)" "unprognostic (2.55e-1)" "unprognostic (1.19e-2)" "unprognostic (4.10e-2)" "unprognostic (7.96e-2)" "unprognostic (6.13e-2)" "unprognostic (5.55e-3)" 10.4 0.1 0.2 0.1 0.2 0.1 3.3 0.1 0.6 0.2 0.3 0.0 0.0 0.1 0.1 20.1 6.2 0.1 0.1 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.0 0.1 0.2 0.1 0.1 0.1 0.0 4.5 0.1 0.0 8.1 0.1 739.9 0.2 0.5 0.1 0.2 0.1 0.2 0.3 0.0 0.0 2.7 164.9 9.7 0.1 0.1 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.2 0.0 0.0 0.3 0.0 0.1 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.0 0.0 0.7 1.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.1 0.6 0.2 0.2 0.2 0.0 0.0 0.0 NCAM2 "MGC51008, NCAM21" ENSG00000154654 "Neural cell adhesion molecule 2" O15394 21 20998315-21543329 "Plasma proteins, Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 15.9;brain: 52.7" "Cell line enriched" "Detected in some" 4 "T-47d: 44.1" "Cancer enhanced" "Detected in some" "glioma: 5.5" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA030900, HPA030901" Enhanced Supported Supported "Nuclear bodies,Plasma membrane" 100000000 "Nuclear bodies, Plasma membrane" "HPA030900: AB_10602037, HPA030901: " "unprognostic (9.70e-2)" "unprognostic (1.08e-1)" "unprognostic (1.47e-1)" "unprognostic (2.54e-2)" "unprognostic (1.85e-1)" "unprognostic (1.81e-1)" "unprognostic (1.37e-2)" "unprognostic (3.01e-2)" "unprognostic (5.90e-2)" "unprognostic (1.62e-1)" "unprognostic (1.31e-1)" "unprognostic (5.61e-1)" "unprognostic (3.07e-4)" "unprognostic (2.47e-4)" "unprognostic (1.62e-1)" "unprognostic (8.05e-2)" "unprognostic (1.35e-3)" 2.0 15.9 25.8 2.0 22.3 1.1 3.1 7.0 52.7 3.3 2.1 14.7 0.0 1.3 2.3 1.8 1.7 1.8 2.6 3.1 18.7 13.9 1.3 9.1 4.4 1.2 21.6 19.4 1.4 1.3 1.1 1.0 1.7 17.9 2.2 2.4 0.5 1.8 2.3 1.5 2.0 1.9 2.7 17.3 2.0 1.3 8.3 26.6 0.0 1.5 0.0 1.3 1.4 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 2.3 2.3 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.6 0.0 0.2 0.6 0.0 1.1 0.0 0.0 5.6 0.0 1.7 0.0 0.0 5.1 1.1 0.1 7.1 0.1 0.0 0.2 0.0 0.5 0.0 2.1 0.0 0.0 0.0 2.6 0.0 0.3 0.3 44.1 3.3 0.0 0.6 0.4 0.0 0.0 0.3 0.0 0.0 1.2 0.0 10.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 25.8 22.3 7.0 22.4 18.7 13.9 21.6 19.4 17.9 26.6 NEFL "CMT1F, CMT2E, NF68, NFL, PPP1R110" ENSG00000277586 "Neurofilament light" P07196 8 24950955-24957110 "Disease related genes, Predicted intracellular proteins" "Charcot-Marie-Tooth disease, Disease mutation, Neurodegeneration, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 7 "brain: 95.1" "Group enriched" "Detected in some" 5 "HEK 293: 112.2;PC-3: 30.1" "Cancer enhanced" "Detected in many" "renal cancer: 24.0" "Cell type enriched" "Detected in some" 5 "memory CD4 T-cell: 13.7" "Lineage enriched" "Detected in single" 138 "T-cells: 13.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA014850, HPA015021" Enhanced Supported Approved "Nuclear speckles,Intermediate filaments" "Nuclear speckles" "Intermediate filaments" "HPA014850: AB_1854397, HPA015021: " "unprognostic (7.63e-2)" "unprognostic (1.36e-2)" "unprognostic (9.53e-2)" "unprognostic (6.81e-2)" "unprognostic (2.82e-2)" "unprognostic (6.69e-2)" "unprognostic (3.69e-2)" "unprognostic (3.78e-3)" "unprognostic (3.06e-1)" "unprognostic (1.60e-1)" "unprognostic (1.46e-2)" "unprognostic (1.94e-1)" "prognostic unfavourable (4.91e-4)" "unprognostic (5.76e-3)" "unprognostic (7.88e-2)" "unprognostic (3.97e-3)" "unprognostic (3.17e-3)" 0.7 12.0 10.3 1.4 20.1 0.6 0.6 2.3 92.1 1.8 1.8 3.0 0.0 1.0 0.7 0.8 3.8 0.7 0.6 0.6 14.1 3.5 0.6 0.6 0.7 0.0 23.8 0.7 0.7 0.6 0.0 0.6 95.1 1.6 1.5 5.0 0.6 9.5 0.6 0.7 1.7 1.2 18.0 0.7 1.1 1.6 2.1 0.0 1.0 0.0 0.8 0.6 0.0 0.0 0.0 0.0 0.0 0.0 13.7 2.1 0.0 0.1 14.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.1 0.0 0.1 0.0 0.0 112.2 0.0 0.0 0.0 4.9 0.0 0.1 1.8 0.4 0.0 0.3 0.0 0.0 0.0 0.4 0.0 0.0 0.0 3.8 30.1 0.0 0.0 0.0 6.9 1.0 6.2 6.4 2.6 0.0 0.4 0.0 0.0 0.0 0.6 7.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 13.7 1.5 0.0 0.0 3.0 0.1 0.0 0.0 0.0 0.0 0.2 2.1 NPTX1 ENSG00000171246 "Neuronal pentraxin 1" Q15818 17 80467148-80477843 "Predicted secreted proteins, Transporters" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 8 "brain: 68.9" "Cell line enhanced" "Detected in some" "HAP1: 12.1;HeLa: 9.5;SiHa: 15.4;U-138 MG: 33.0;WM-115: 45.3" "Cancer enhanced" "Detected in many" "glioma: 4.8" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 4 "NK-cell: 1.5" "Lineage enriched" "Detected in single" 4 "NK-cells: 1.5" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 4 "amygdala: 74.8;cerebellum: 228.3;cerebral cortex: 119.6;hippocampal formation: 173.6" HPA077062 Enhanced "Secreted in brain" 1000000 "HPA077062: " "unprognostic (2.37e-2)" "unprognostic (1.18e-1)" "unprognostic (1.81e-2)" "unprognostic (6.95e-2)" "unprognostic (4.16e-3)" "unprognostic (2.43e-2)" "unprognostic (1.48e-2)" "unprognostic (3.63e-1)" "unprognostic (1.31e-2)" "unprognostic (2.07e-1)" "unprognostic (1.81e-2)" "unprognostic (9.63e-3)" "unprognostic (1.05e-6)" "unprognostic (1.41e-4)" "unprognostic (1.35e-1)" "unprognostic (8.86e-6)" "unprognostic (2.71e-3)" 1.0 3.4 28.8 1.4 14.7 0.8 1.1 68.9 62.5 0.8 9.1 0.2 0.0 1.3 1.3 2.5 1.4 1.4 1.7 0.7 15.5 3.0 0.8 0.7 1.0 1.4 1.0 18.2 0.7 0.7 0.7 0.8 1.6 4.6 1.3 2.5 0.6 0.7 2.9 1.0 3.2 1.5 1.4 1.9 2.3 1.5 1.3 0.0 0.9 0.7 0.0 0.7 0.9 0.2 0.0 0.0 0.0 0.0 1.5 0.3 0.1 0.0 0.7 0.2 0.0 0.1 0.2 0.0 0.7 0.0 0.0 0.0 0.2 0.1 0.0 0.1 0.1 0.0 12.1 0.0 0.0 0.0 7.5 0.0 9.5 0.0 0.0 0.0 0.5 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 2.5 0.0 0.0 3.1 0.0 0.0 8.2 0.0 15.4 0.0 0.0 0.0 0.2 0.1 33.0 0.0 1.5 0.0 0.0 0.0 0.0 0.1 0.0 45.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.1 28.8 14.7 68.9 29.9 15.5 3.0 1.0 18.2 4.6 0.0 NPTXR ENSG00000221890 "Neuronal pentraxin receptor" O95502 22 38818452-38843982 "Plasma proteins, Predicted intracellular proteins" Receptor "Evidence at protein level" "Evidence at protein level" "No human protein/transcript evidence" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 7 "brain: 73.6" "Cell line enhanced" "Detected in many" "SCLC-21H: 14.8;SiHa: 11.0;U-87 MG: 42.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" HPA001079 Enhanced Approved "Nucleoplasm,Plasma membrane,Cytosol" "Intracellular and membrane" 280000 "Plasma membrane, Cytosol" Nucleoplasm "HPA001079: AB_1078414" "unprognostic (6.29e-2)" "prognostic favourable (3.93e-4)" "unprognostic (6.82e-3)" "prognostic unfavourable (2.85e-4)" "unprognostic (9.55e-2)" "unprognostic (6.93e-2)" "unprognostic (1.05e-1)" "unprognostic (1.51e-1)" "unprognostic (1.65e-2)" "unprognostic (1.71e-1)" "unprognostic (1.52e-3)" "unprognostic (1.37e-1)" "unprognostic (1.27e-1)" "unprognostic (1.49e-2)" "unprognostic (9.22e-2)" "unprognostic (8.65e-2)" "unprognostic (2.77e-2)" 2.3 3.8 39.1 1.8 17.5 0.8 1.9 16.2 73.6 5.8 2.6 4.3 0.5 1.5 5.6 3.3 2.7 6.1 2.0 10.5 57.4 15.2 1.3 0.8 1.7 1.6 5.6 20.7 6.2 3.6 5.9 2.0 0.9 4.5 6.2 1.7 1.0 3.2 5.6 0.9 1.2 1.4 5.7 3.3 2.1 2.0 1.6 4.0 0.0 2.5 0.0 1.6 2.5 1.9 0.3 0.2 0.6 0.2 0.6 2.3 0.4 0.4 2.9 0.1 0.8 5.9 0.6 0.0 1.9 0.4 3.8 1.3 2.9 0.6 0.0 3.4 0.5 0.4 0.8 0.1 1.2 0.2 1.0 0.0 0.1 4.4 0.6 0.0 0.1 1.9 0.1 3.4 0.0 0.1 3.5 0.1 0.1 4.4 0.0 0.2 3.5 1.0 0.7 0.0 6.9 0.9 7.9 14.8 0.9 11.0 0.0 0.3 4.7 1.1 0.2 6.8 4.2 0.0 0.3 1.0 0.0 0.0 42.5 8.6 3.5 0.5 0.2 0.1 1.8 0.0 1.3 0.1 1.0 2.3 0.0 0.3 1.5 1.2 0.6 0.6 0.1 0.2 0.0 0.4 39.1 17.5 16.2 49.0 57.4 15.2 5.6 20.7 4.5 4.0 OPRK1 "KOR, OPRK" ENSG00000082556 "Opioid receptor kappa 1" P41145 8 53225716-53251697 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" Behavior "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 18.0;prostate: 6.7" "Cell line enriched" "Detected in some" 5 "U-937: 21.6" "Cancer enhanced" "Detected in some" "prostate cancer: 1.8" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "basophil: 1.2" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA067549 Enhanced Supported "Nucleoplasm,Plasma membrane,Cytosol" "Plasma membrane" "Nucleoplasm, Cytosol" "HPA067549: " "unprognostic (1.01e-1)" "unprognostic (1.17e-2)" "unprognostic (8.70e-3)" "unprognostic (3.73e-2)" "unprognostic (6.74e-2)" "unprognostic (2.22e-3)" "unprognostic (8.09e-2)" "unprognostic (9.71e-2)" "unprognostic (4.28e-3)" "unprognostic (3.29e-1)" "unprognostic (3.35e-2)" "unprognostic (9.54e-4)" "unprognostic (1.61e-1)" 0.7 0.7 15.9 0.3 18.0 0.4 0.3 2.2 8.8 0.4 0.4 0.3 0.0 0.4 0.4 0.6 0.5 0.7 0.4 0.8 4.5 6.2 0.3 0.5 0.8 0.4 1.7 5.8 0.4 0.3 0.4 0.8 2.8 3.1 6.7 0.4 0.0 0.3 0.4 3.8 0.4 0.5 0.5 0.5 0.6 0.3 2.8 1.6 0.2 0.9 0.0 0.3 0.3 0.1 0.2 0.8 1.2 0.2 0.1 0.4 0.0 0.0 0.0 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.3 21.6 0.1 1.2 0.2 0.1 0.4 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.0 0.0 0.4 0.1 0.1 0.8 0.0 0.0 15.9 18.0 2.2 8.8 4.5 6.2 1.7 5.8 3.1 1.6 PCDH11X "PCDH-X, PCDH11, PCDHX, PPP1R119" ENSG00000102290 "Protocadherin 11 X-linked" Q9BZA7 X 91779261-92623230 "Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "brain: 7.0;ovary: 12.6;parathyroid gland: 5.2" "Group enriched" "Detected in some" 5 "AF22: 4.2;AN3-CA: 6.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA077495 Approved "HPA077495: " "unprognostic (4.22e-3)" "unprognostic (1.16e-1)" "unprognostic (1.39e-4)" "unprognostic (1.18e-1)" "unprognostic (8.20e-3)" "unprognostic (6.32e-2)" "unprognostic (9.10e-2)" "unprognostic (6.19e-2)" "unprognostic (4.58e-1)" "unprognostic (1.58e-1)" "unprognostic (2.45e-2)" "unprognostic (3.86e-1)" 0.0 0.3 2.6 0.1 7.0 0.0 0.2 0.0 4.8 1.7 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.8 4.2 0.0 0.0 0.0 0.2 1.3 12.6 0.0 5.2 0.3 1.2 0.0 0.0 0.0 0.4 0.0 0.1 0.0 0.3 0.1 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.2 6.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 PCDHGC5 PCDH-GAMMA-C5 ENSG00000240764 "Protocadherin gamma subfamily C, 5" Q9Y5F6 5 141489121-141512979 "Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 15 "brain: 43.7" "Cell line enhanced" "Detected in some" "U-138 MG: 16.3;U-251 MG: 7.0;U-87 MG: 10.0" "Group enriched" "Detected in some" 13 "glioma: 3.1;head and neck cancer: 0.8" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "amygdala: 129.6;basal ganglia: 118.6;cerebral cortex: 130.2;hippocampal formation: 113.0;olfactory region: 85.4" "HPA008755, HPA010580, HPA076140" Supported Uncertain "Nucleoplasm,Vesicles,Plasma membrane,Cytosol" "Vesicles, Plasma membrane" "Nucleoplasm, Cytosol" "HPA008755: AB_1079577, HPA010580: , HPA076140: " "unprognostic (2.86e-3)" "unprognostic (7.63e-4)" "unprognostic (2.00e-1)" "unprognostic (3.52e-3)" "unprognostic (5.42e-2)" "unprognostic (1.14e-1)" "unprognostic (5.65e-2)" "unprognostic (2.38e-2)" "unprognostic (2.14e-1)" "unprognostic (3.16e-2)" "unprognostic (3.90e-1)" "unprognostic (1.66e-2)" "unprognostic (1.01e-9)" "unprognostic (6.87e-3)" "unprognostic (3.89e-2)" "unprognostic (3.13e-1)" "unprognostic (3.77e-3)" 1.0 1.1 7.4 1.1 34.5 0.9 1.1 3.0 43.7 1.1 1.0 2.8 0.0 0.9 1.4 1.3 1.0 1.2 1.2 2.8 11.8 2.8 0.9 0.9 1.1 0.9 2.2 10.0 1.1 1.0 1.0 1.1 1.0 2.3 1.3 1.0 0.0 0.9 1.6 1.6 1.5 0.9 2.0 0.8 1.0 1.0 1.3 1.1 0.0 1.0 0.0 1.0 1.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.4 1.7 0.2 0.8 0.6 0.5 0.6 0.0 0.0 0.5 1.6 2.4 0.1 0.0 0.4 0.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 3.6 0.0 0.0 0.0 0.0 1.1 0.1 0.0 0.0 0.0 0.9 0.8 0.3 0.0 0.0 0.0 0.2 0.4 0.0 0.0 0.0 0.1 0.2 0.1 16.3 0.2 0.2 7.0 0.0 0.0 0.0 10.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.4 34.5 3.0 39.2 11.8 2.8 2.2 10.0 2.3 1.1 PCP4L1 IQM1 ENSG00000248485 "Purkinje cell protein 4 like 1" A6NKN8 1 161258727-161285450 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "No human protein/transcript evidence" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 67.7;urinary bladder: 33.2" "Group enriched" "Detected in some" 6 "RT4: 15.7;T-47d: 10.3" "Group enriched" "Detected in many" 6 "cervical cancer: 12.4;head and neck cancer: 5.1;lung cancer: 13.6;testis cancer: 18.9;urothelial cancer: 21.8" "Group enriched" "Detected in all" 5 "basal ganglia: 67.7;cerebral cortex: 17.9;pons and medulla: 30.8" "Cell type enhanced" "Detected in single" "T-reg: 3.1" "Lineage enhanced" "Detected in single" "T-cells: 3.1" "Low region specificity" "Detected in all" HPA052833 Enhanced Supported Approved Nucleoplasm,Mitochondria "Nucleoplasm, Mitochondria" "HPA052833: " "unprognostic (1.81e-2)" "unprognostic (9.39e-2)" "unprognostic (5.25e-2)" "unprognostic (2.07e-1)" "unprognostic (3.03e-2)" "unprognostic (1.87e-2)" "unprognostic (2.51e-1)" "prognostic favourable (8.10e-5)" "unprognostic (2.39e-1)" "unprognostic (1.92e-1)" "unprognostic (4.93e-2)" "unprognostic (7.37e-2)" "unprognostic (3.63e-5)" "unprognostic (4.81e-2)" "unprognostic (1.25e-1)" "unprognostic (2.09e-1)" "unprognostic (6.15e-2)" 3.2 1.0 5.7 1.3 67.7 0.6 2.2 4.4 28.9 4.3 4.3 1.4 1.5 2.2 2.2 3.3 16.5 2.1 3.9 1.3 3.9 6.3 1.0 4.3 5.0 0.7 7.8 4.6 2.6 0.5 0.6 21.9 0.9 30.8 5.5 3.2 5.9 1.2 17.8 1.0 2.8 3.3 6.8 7.5 0.8 1.2 2.3 5.3 0.0 1.0 0.0 3.0 33.2 4.1 0.0 0.7 0.0 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 1.9 0.0 0.0 0.0 0.0 0.0 2.1 0.4 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.3 0.0 0.1 0.0 0.1 0.0 15.7 2.2 0.0 0.0 0.3 0.0 10.3 0.4 0.2 0.0 0.0 0.0 0.0 0.9 1.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.0 5.7 67.7 4.4 17.9 3.9 6.3 7.8 4.6 30.8 5.3 PDE1B PDES1B ENSG00000123360 "Phosphodiesterase 1B" Q01064 12 54549350-54579239 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Calmodulin-binding, Hydrolase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 52.6" "Cell line enhanced" "Detected in some" "HDLM-2: 11.3;HL-60: 6.3;HMC-1: 12.1;NB-4: 8.0;THP-1: 7.7;U-937: 6.4" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in all" "basal ganglia: 52.6" "Cell type enriched" "Detected in single" 4 "naive CD4 T-cell: 1.6" "Lineage enriched" "Detected in single" 4 "T-cells: 1.6" "Region enriched" "Detected in all" 6 "basal ganglia: 895.2" "Region enriched" "Detected in all" 7 "basal ganglia: 253.8" HPA018492 Enhanced "HPA018492: AB_1855119" "unprognostic (2.90e-1)" "unprognostic (1.51e-1)" "unprognostic (7.67e-4)" "unprognostic (5.63e-3)" "unprognostic (7.02e-2)" "unprognostic (7.51e-2)" "unprognostic (1.97e-1)" "unprognostic (9.39e-2)" "unprognostic (1.14e-1)" "unprognostic (5.11e-2)" "unprognostic (3.84e-3)" "unprognostic (2.70e-2)" "prognostic unfavourable (4.77e-6)" "unprognostic (6.64e-4)" "unprognostic (2.14e-1)" "unprognostic (3.09e-1)" "unprognostic (2.83e-2)" 12.3 1.4 9.9 4.6 52.6 5.6 2.7 3.1 19.4 2.6 3.7 1.4 0.0 1.2 3.9 2.5 1.7 2.4 2.9 1.9 3.7 3.8 1.3 1.6 2.9 1.6 3.0 9.3 12.5 0.6 11.0 0.5 0.5 5.8 1.0 1.7 0.5 1.3 2.1 0.7 1.0 2.6 4.9 1.2 4.8 2.5 1.1 7.7 0.0 2.7 0.0 1.1 2.8 1.1 0.2 0.3 0.1 0.3 0.1 1.6 0.4 0.0 0.0 0.5 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.0 0.1 0.0 0.0 1.8 0.0 0.0 11.3 0.3 4.6 0.0 0.0 0.0 6.3 12.1 0.7 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.7 8.0 3.3 0.0 2.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 7.7 0.0 0.0 0.2 0.0 0.0 0.0 0.1 2.4 0.0 6.4 1.2 0.0 0.3 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.3 0.2 1.6 0.0 0.1 0.1 0.0 0.0 0.0 0.4 9.9 52.6 3.1 19.4 3.7 3.8 3.0 9.3 5.8 7.7 PDYN "ADCA, PENKB, SCA23" ENSG00000101327 Prodynorphin P01213 20 1978757-1994285 "Disease related genes, Potential drug targets, Predicted secreted proteins, Transporters" "Endorphin, Neuropeptide, Neurotransmitter, Opioid peptide" "Disease mutation, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 17 "brain: 55.9" "Cell line enhanced" "Detected in some" "AF22: 1.5;NTERA-2: 2.8;THP-1: 2.6" "Group enriched" "Detected in some" 29 "glioma: 2.6;ovarian cancer: 1.6" "Region enriched" "Detected in many" 4 "basal ganglia: 55.9" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 4 "basal ganglia: 150.7;hypothalamus: 70.9" "Region enhanced" "Detected in many" "basal ganglia: 131.1" "HPA053342, CAB079777" Enhanced Supported "Secreted in brain" "CAB079777: , HPA053342: " "unprognostic (7.00e-2)" "unprognostic (1.07e-1)" "unprognostic (1.40e-1)" "unprognostic (3.73e-2)" 0.4 0.4 13.2 0.4 55.9 0.4 0.4 0.0 40.3 0.4 0.4 1.2 0.0 0.4 0.4 0.4 0.4 0.4 0.4 0.4 5.0 3.9 0.4 0.4 0.4 0.4 0.7 3.7 0.4 0.4 0.4 0.0 0.4 0.2 0.4 0.4 0.0 0.4 0.4 0.4 0.6 0.4 0.4 2.2 0.4 0.4 3.2 1.1 0.0 0.5 0.0 0.4 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.2 55.9 0.0 3.8 5.0 3.9 0.7 3.7 0.2 1.1 PNOC "N/OFQ, NOP, PPNOC" ENSG00000168081 Prepronociceptin Q13519 8 28316986-28343355 "Predicted intracellular proteins, Predicted secreted proteins" "Neuropeptide, Neurotransmitter, Opioid peptide" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 47.9;brain: 22.6;lymphoid tissue: 18.1" "Group enriched" "Detected in some" 6 "Daudi: 24.0;Karpas-707: 18.9;RPMI-8226: 7.0;U-698: 14.5" "Cancer enriched" "Detected in many" 8 "ovarian cancer: 32.2" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 17 "memory B-cell: 46.6;naive B-cell: 47.9;plasmacytoid DC: 33.7" "Group enriched" "Detected in many" 17 "B-cells: 47.9;dendritic cells: 33.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA044507, HPA056724" Enhanced "Secreted to blood" 12325 "HPA044507: AB_10795043, HPA056724: AB_2683216" "unprognostic (1.11e-1)" "unprognostic (1.77e-3)" "unprognostic (3.53e-2)" "prognostic unfavourable (2.94e-6)" "unprognostic (3.71e-2)" "unprognostic (5.16e-5)" "unprognostic (1.03e-1)" "unprognostic (1.50e-1)" "unprognostic (7.81e-4)" "unprognostic (1.48e-1)" "unprognostic (1.66e-1)" "unprognostic (9.99e-3)" "unprognostic (7.57e-9)" "unprognostic (2.19e-2)" "unprognostic (5.45e-1)" "unprognostic (3.44e-1)" "unprognostic (1.40e-1)" 0.4 0.6 4.0 7.2 7.4 2.0 0.5 0.9 22.6 0.3 2.3 1.0 0.0 3.3 0.2 0.0 1.2 13.5 0.9 0.3 3.1 8.4 1.2 0.4 0.9 18.1 5.9 3.2 2.2 0.2 0.1 0.2 0.0 7.5 0.3 1.3 0.0 2.5 0.1 0.2 0.2 6.5 0.4 4.3 16.9 2.4 0.7 0.0 0.6 0.6 0.0 18.1 5.2 0.4 47.9 33.7 0.4 2.4 0.2 0.1 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 18.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 2.6 2.6 14.5 0.1 0.1 0.0 0.0 2.4 0.4 0.0 1.5 0.0 46.6 0.0 0.0 0.2 47.9 0.0 0.0 0.2 0.2 0.6 33.7 0.1 2.4 4.0 7.4 0.9 15.7 3.1 8.4 5.9 3.2 7.5 0.0 PTN "HBGF8, HBNF, NEGF1" ENSG00000105894 Pleiotrophin P21246 7 137227341-137343865 "Cancer-related genes, Predicted secreted proteins" "Growth factor, Heparin-binding, Mitogen" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "parathyroid gland: 160.7" "Cell line enriched" "Detected in some" 12 "AF22: 186.3" "Cancer enriched" "Detected in all" 11 "glioma: 514.1" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017685, HPA073913" Enhanced Supported "Endoplasmic reticulum" "Secreted to blood" 166965 1800000 "Endoplasmic reticulum" "CAB017685: AB_1128556, HPA073913: " "unprognostic (1.51e-2)" "unprognostic (7.87e-2)" "unprognostic (5.44e-2)" "unprognostic (4.23e-2)" "unprognostic (1.92e-1)" "unprognostic (7.19e-2)" "unprognostic (2.81e-2)" "unprognostic (7.29e-2)" "unprognostic (1.30e-1)" "unprognostic (1.09e-2)" "unprognostic (3.86e-1)" "unprognostic (1.22e-2)" "prognostic favourable (1.35e-4)" "unprognostic (2.34e-1)" "unprognostic (1.18e-1)" "unprognostic (1.03e-1)" "unprognostic (1.16e-2)" 7.8 6.6 55.5 2.0 43.3 0.9 27.7 38.6 58.5 30.7 7.2 26.9 9.9 2.5 25.2 18.7 25.0 7.2 18.2 29.4 42.3 29.7 12.7 3.4 6.5 2.6 31.6 27.0 7.2 3.4 160.7 52.5 11.8 31.4 38.5 7.7 19.0 12.0 18.1 1.5 3.6 4.0 17.7 23.4 12.4 5.4 16.8 23.3 1.3 5.1 8.7 5.3 7.7 18.4 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.1 0.0 186.3 2.2 0.0 0.1 15.2 4.8 14.3 2.7 3.7 0.0 0.0 0.0 0.0 6.3 0.1 0.0 0.0 2.0 0.0 0.1 0.0 0.0 0.0 0.8 0.0 0.0 0.2 0.0 1.8 0.0 0.0 0.0 0.8 0.7 0.0 0.0 0.0 14.4 0.1 0.0 0.3 0.0 0.0 0.0 0.8 12.7 0.0 0.0 0.0 0.0 0.0 0.0 4.1 3.6 0.1 10.3 0.0 0.0 0.0 13.1 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 55.5 43.3 38.6 42.0 42.3 29.7 31.6 27.0 31.4 23.3 PTPRN "IA-2, ICA512" ENSG00000054356 "Protein tyrosine phosphatase, receptor type N" Q16849 2 219289623-219309648 "Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Transcription, Transcription regulation" Receptor "Diabetes mellitus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 89.6;pancreas: 28.9;pituitary gland: 43.4" "Group enriched" "Detected in some" 8 "U-2 OS: 19.8;U-87 MG: 73.7" "Group enriched" "Detected in some" 12 "glioma: 5.3;pancreatic cancer: 18.4" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007152, HPA007179" Enhanced Approved "Endoplasmic reticulum" "Endoplasmic reticulum" "HPA007152: , HPA007179: AB_1079714" "unprognostic (1.43e-1)" "unprognostic (1.33e-4)" "unprognostic (2.91e-3)" "unprognostic (5.83e-3)" "prognostic unfavourable (1.45e-7)" "unprognostic (3.64e-2)" "unprognostic (1.24e-4)" "unprognostic (1.58e-3)" "unprognostic (1.02e-1)" "unprognostic (6.20e-4)" "unprognostic (1.44e-2)" "unprognostic (1.54e-1)" "unprognostic (2.28e-10)" "unprognostic (1.43e-2)" "unprognostic (2.49e-1)" "unprognostic (1.10e-2)" "unprognostic (8.61e-2)" 1.7 22.3 19.3 4.7 35.7 1.7 1.3 17.3 89.6 1.2 2.4 2.5 0.0 2.5 1.5 1.2 1.5 1.3 1.5 1.4 21.6 40.1 1.5 1.2 1.4 1.3 14.4 19.8 1.3 28.9 1.2 43.4 1.4 22.0 1.4 1.9 3.1 1.2 1.3 1.2 2.0 2.5 2.4 3.5 1.3 6.0 1.4 2.1 0.0 1.5 0.0 1.2 2.7 0.0 0.1 0.3 0.2 0.0 0.0 0.6 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.2 0.0 0.0 0.0 0.0 0.3 1.3 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.5 0.0 0.1 2.5 0.0 6.1 0.0 0.0 0.1 0.1 0.4 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 4.8 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.8 0.0 0.0 0.0 0.0 0.2 73.7 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.1 0.3 0.1 0.0 0.4 0.2 0.0 0.0 0.0 0.6 3.7 19.3 35.7 17.3 54.0 21.6 40.1 14.4 19.8 22.0 2.1 PTPRZ1 "phosphacan, PTP18, PTPRZ, PTPZ, RPTPB" ENSG00000106278 "Protein tyrosine phosphatase, receptor type Z1" P23471 7 121873089-122062036 "Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" "Hydrolase, Protein phosphatase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 118.1" "Group enriched" "Detected in some" 9 "AF22: 92.1;NTERA-2: 25.6;WM-115: 40.3" "Cancer enriched" "Detected in many" 14 "glioma: 175.5" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA015103 Enhanced Approved Vesicles,Cytosol "Secreted in brain" 950000 Cytosol Vesicles "HPA015103: AB_1855946" "unprognostic (8.49e-4)" "unprognostic (3.96e-3)" "unprognostic (4.11e-2)" "unprognostic (1.37e-1)" "unprognostic (9.18e-2)" "unprognostic (2.41e-2)" "unprognostic (8.30e-3)" "unprognostic (3.78e-2)" "unprognostic (1.57e-1)" "unprognostic (2.53e-1)" "unprognostic (9.17e-4)" "unprognostic (1.83e-1)" "unprognostic (8.72e-6)" "unprognostic (2.00e-1)" "unprognostic (2.16e-1)" "unprognostic (8.77e-2)" "prognostic unfavourable (9.36e-4)" 2.0 2.5 33.1 2.3 44.1 1.5 4.0 15.4 118.1 2.4 2.2 19.3 0.0 1.9 1.6 2.0 7.0 1.7 1.9 2.0 39.6 15.9 1.6 1.6 2.1 1.5 18.6 17.8 2.0 3.3 1.5 1.6 1.6 67.6 2.1 2.3 0.8 2.4 2.0 1.5 19.3 1.9 2.4 76.6 2.1 9.8 1.7 23.6 0.0 1.5 1.8 3.0 2.2 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 92.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 5.8 0.0 0.0 0.2 0.0 0.0 0.0 0.0 25.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.3 1.1 0.0 0.1 0.0 40.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 33.1 44.1 15.4 39.6 39.6 15.9 18.6 17.8 67.6 23.6 REEP2 "C5orf19, SGC32445, SPG72, Yip2d" ENSG00000132563 "Receptor accessory protein 2" Q9BRK0 5 138439017-138446969 "Disease related genes, Predicted membrane proteins" "Disease mutation, Hereditary spastic paraplegia, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 58.9" "Cell line enhanced" "Detected in many" "AN3-CA: 41.4;SCLC-21H: 17.3;SH-SY5Y: 19.6;U-87 MG: 15.6" "Cancer enriched" "Detected in many" 9 "glioma: 31.0" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "T-reg: 3.2" "Group enriched" "Detected in many" 21 "dendritic cells: 1.0;T-cells: 3.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA031813, HPA076571" Enhanced "HPA031813: , HPA076571: " "prognostic favourable (7.83e-5)" "unprognostic (1.11e-2)" "unprognostic (3.97e-6)" "unprognostic (3.70e-3)" "prognostic unfavourable (6.65e-4)" "unprognostic (5.43e-2)" "unprognostic (1.62e-2)" "unprognostic (1.04e-1)" "prognostic favourable (9.31e-4)" "unprognostic (5.93e-2)" "unprognostic (3.70e-3)" "unprognostic (9.78e-2)" "unprognostic (6.54e-3)" "unprognostic (7.54e-2)" "unprognostic (1.47e-3)" "unprognostic (6.19e-3)" "unprognostic (1.13e-3)" 5.2 10.9 27.2 3.4 27.2 1.2 2.0 37.0 58.9 3.0 4.4 5.9 0.4 2.8 3.7 2.6 5.6 2.8 3.6 10.5 29.3 32.1 1.6 1.0 1.5 1.4 27.9 19.6 3.5 2.9 2.8 13.9 1.6 25.8 6.1 3.3 7.9 2.1 9.9 15.6 2.0 3.1 13.6 9.7 1.2 2.2 4.5 6.3 0.0 1.4 0.5 1.5 4.1 1.1 0.0 1.0 0.0 0.0 0.0 3.2 0.3 0.2 3.1 11.9 41.4 1.8 4.6 0.0 3.6 1.6 4.9 5.6 2.2 0.4 0.0 0.6 4.4 0.2 11.2 2.3 3.8 1.2 9.9 0.0 0.8 5.4 4.4 0.0 0.0 1.5 0.1 2.8 0.2 0.9 0.0 3.0 1.6 1.8 1.0 0.7 7.3 0.1 4.0 1.1 0.0 0.9 0.0 17.3 19.6 1.2 0.0 3.0 1.1 0.4 0.1 2.8 2.9 2.6 6.6 7.7 4.8 0.3 15.6 0.0 0.1 0.0 0.0 0.0 0.4 0.0 0.2 0.0 0.2 1.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 1.0 3.2 0.3 27.2 27.2 37.0 35.6 29.3 32.1 27.9 19.6 25.8 6.3 SCCPDH "CGI-49, NET11" ENSG00000143653 "Saccharopine dehydrogenase (putative)" Q8NBX0 1 246724047-246768137 "Predicted membrane proteins" Oxidoreductase "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 95.3" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 17 "basophil: 95.3" "Lineage enriched" "Detected in all" 22 "granulocytes: 95.3" "Low region specificity" "Detected in all" "HPA050775, HPA076030" Enhanced Approved Vesicles 2100000 Vesicles "HPA050775: , HPA076030: " "unprognostic (4.25e-1)" "unprognostic (3.11e-1)" "unprognostic (1.22e-1)" "unprognostic (1.75e-2)" "unprognostic (2.83e-2)" "unprognostic (6.43e-2)" "unprognostic (1.25e-1)" "unprognostic (1.10e-1)" "unprognostic (1.60e-1)" "unprognostic (5.51e-2)" "unprognostic (1.93e-1)" "unprognostic (3.60e-1)" "unprognostic (2.70e-2)" "unprognostic (9.63e-2)" "unprognostic (1.13e-1)" "unprognostic (2.24e-1)" "unprognostic (3.93e-2)" 14.1 25.8 15.7 6.4 17.5 13.4 11.3 11.3 20.5 10.9 11.7 24.7 8.5 15.1 12.0 8.5 4.8 14.4 9.7 15.8 15.6 19.8 23.0 67.3 9.3 7.3 26.1 15.0 10.6 12.7 15.0 12.7 14.1 21.7 18.1 12.2 7.3 7.4 16.7 23.9 10.7 15.3 10.8 62.1 5.1 12.4 65.1 17.5 8.5 18.2 7.3 4.8 25.0 13.2 1.4 2.3 95.3 3.2 4.2 3.0 2.1 12.8 12.6 9.2 5.5 11.0 14.0 0.1 10.1 14.1 17.1 14.3 7.7 36.3 6.8 13.3 11.6 4.2 7.8 3.0 17.6 9.5 2.8 11.6 11.5 15.3 10.4 22.5 10.0 9.3 1.4 11.5 1.2 18.3 14.4 0.0 17.0 3.1 23.4 28.6 13.8 10.0 19.7 11.8 0.0 52.5 30.4 10.5 11.8 13.7 0.6 8.9 10.2 23.5 11.9 7.9 7.1 19.2 26.0 34.1 11.7 4.1 13.5 30.7 10.4 95.3 3.2 5.5 2.5 2.8 3.0 1.4 0.7 2.1 1.3 1.1 1.0 3.0 0.8 4.2 1.8 2.3 0.5 2.1 15.7 17.5 11.3 20.5 15.6 19.8 26.1 15.0 21.7 17.5 SCG2 "CHGC, SgII, SN" ENSG00000171951 "Secretogranin II" P13521 2 223596940-223602503 "Plasma proteins, Predicted secreted proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "adrenal gland: 133.0;brain: 94.1;pituitary gland: 76.5" "Cell line enhanced" "Detected in some" "ASC TERT1: 26.2;HSkMC: 22.4;SCLC-21H: 22.8;SH-SY5Y: 9.9;WM-115: 16.7" "Group enriched" "Detected in many" 8 "glioma: 70.0;pancreatic cancer: 52.9" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA011893, HPA075062" Enhanced Supported Approved "Golgi apparatus,Vesicles" "Secreted to blood" 54000 "Golgi apparatus" Vesicles "HPA011893: AB_1856656, HPA075062: AB_2732277" "unprognostic (2.93e-2)" "unprognostic (1.44e-2)" "unprognostic (1.23e-3)" "unprognostic (6.82e-4)" "unprognostic (2.51e-2)" "unprognostic (1.13e-2)" "unprognostic (2.77e-3)" "unprognostic (6.73e-2)" "unprognostic (1.08e-1)" "unprognostic (4.69e-2)" "prognostic favourable (5.58e-4)" "unprognostic (1.34e-1)" "prognostic unfavourable (7.01e-10)" "unprognostic (2.47e-3)" "unprognostic (4.02e-1)" "unprognostic (1.57e-2)" "unprognostic (1.90e-3)" 3.5 133.0 13.3 11.0 94.1 0.9 0.9 5.6 55.9 1.4 5.4 5.8 0.0 17.3 2.1 0.9 1.0 0.8 2.2 1.4 10.5 79.4 1.0 0.8 1.9 0.9 21.7 11.0 1.3 10.7 1.1 76.5 1.1 57.7 2.1 5.5 1.5 0.9 1.3 0.8 1.0 8.0 5.2 10.3 0.8 8.0 0.9 5.0 0.0 3.1 0.0 0.8 1.1 0.2 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 1.4 4.9 4.1 1.1 26.2 0.1 0.2 0.9 1.9 4.9 0.2 0.4 0.0 0.4 0.3 0.1 0.1 0.0 2.5 0.0 0.2 0.0 0.3 0.0 0.3 0.3 2.2 22.4 0.1 2.7 0.9 0.0 0.1 0.2 2.4 0.1 0.0 0.1 3.5 0.0 0.0 0.1 0.0 0.3 0.0 22.8 9.9 0.0 0.2 1.1 0.0 0.0 0.0 2.6 1.0 0.1 1.7 0.0 0.0 0.1 0.7 0.0 16.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 13.3 94.1 5.6 23.0 10.5 79.4 21.7 11.0 57.7 5.0 SEMA5B "FLJ10372, KIAA1445, SEMAG, SemG" ENSG00000082684 "Semaphorin 5B" Q9P283 3 122909193-123028605 "Predicted membrane proteins" "Differentiation, Neurogenesis" "Developmental protein" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 13.6;heart muscle: 11.7" "Cell line enhanced" "Detected in some" "AF22: 41.4;NTERA-2: 8.0;SH-SY5Y: 11.0" "Cancer enhanced" "Detected in many" "renal cancer: 18.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA066548 Enhanced Supported Cytosol Cytosol "HPA066548: " "unprognostic (7.34e-2)" "unprognostic (1.84e-3)" "unprognostic (1.92e-4)" "unprognostic (3.01e-2)" "unprognostic (1.04e-1)" "unprognostic (2.28e-1)" "unprognostic (4.72e-2)" "unprognostic (1.58e-2)" "unprognostic (7.66e-3)" "unprognostic (2.87e-2)" "unprognostic (4.71e-2)" "unprognostic (2.58e-1)" "prognostic unfavourable (7.57e-4)" "unprognostic (1.31e-3)" "unprognostic (5.96e-2)" "unprognostic (6.12e-2)" "unprognostic (2.12e-1)" 1.5 1.2 12.0 0.7 12.3 0.3 1.1 0.8 13.6 2.1 1.5 4.3 0.4 1.9 2.8 5.5 1.5 3.0 4.7 11.7 13.0 3.3 6.1 1.4 2.2 1.1 2.5 3.3 1.3 3.1 1.1 2.5 5.0 2.0 1.8 1.8 6.0 0.9 3.1 1.6 1.2 1.3 3.8 1.7 0.5 0.7 1.1 5.7 0.1 2.2 2.5 1.3 3.3 1.7 0.0 0.0 0.0 0.0 0.0 0.5 0.2 0.0 0.0 41.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 8.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 11.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.2 12.0 12.3 0.8 13.2 13.0 3.3 2.5 3.3 2.0 5.7 SLC6A17 ENSG00000197106 "Solute carrier family 6 member 17" Q9H1V8 1 110150486-110202202 "Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 53.5" "Cell line enriched" "Detected in some" 5 "SK-MEL-30: 27.6" "Cancer enriched" "Detected in some" 9 "melanoma: 17.0" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007663, HPA008044" Enhanced Approved "Nucleoplasm,Nucleoli,Golgi apparatus" "Golgi apparatus" "Nucleoplasm, Nucleoli" "HPA007663: AB_1857194, HPA008044: AB_1857192" "unprognostic (1.13e-1)" "unprognostic (1.37e-3)" "unprognostic (5.52e-3)" "unprognostic (3.00e-2)" "unprognostic (1.17e-1)" "unprognostic (4.88e-2)" "unprognostic (6.11e-3)" "unprognostic (3.87e-3)" "unprognostic (1.70e-2)" "unprognostic (1.80e-1)" "unprognostic (1.68e-2)" "unprognostic (2.94e-1)" "unprognostic (1.89e-2)" "unprognostic (1.73e-2)" "unprognostic (9.76e-2)" "unprognostic (1.38e-3)" "unprognostic (1.68e-3)" 1.4 7.8 9.3 1.2 18.3 1.1 1.3 21.8 53.5 1.0 1.1 2.3 0.0 1.0 1.0 2.1 1.3 1.0 1.1 1.0 11.2 14.9 2.1 0.9 1.0 0.9 6.0 16.2 1.0 2.6 1.0 12.4 1.8 19.5 1.0 1.0 2.6 1.2 1.0 1.0 7.6 1.1 1.1 1.8 1.0 1.8 2.4 0.7 0.0 1.3 0.0 0.9 1.0 0.1 0.3 0.0 0.8 0.0 0.0 0.3 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 4.2 0.4 1.6 0.1 0.0 0.0 0.0 0.2 0.2 0.1 0.0 0.0 1.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 2.2 0.6 4.7 1.4 27.6 0.7 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.0 5.6 0.0 2.5 0.0 0.0 0.5 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 9.3 18.3 21.8 37.3 11.2 14.9 6.0 16.2 19.5 0.7 SLC6A2 "NAT1, NET, NET1, SLC6A5" ENSG00000103546 "Solute carrier family 6 member 2" P23975 16 55655604-55706192 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 20.4;placenta: 41.8" "Cell line enriched" "Detected in some" 30 "SH-SY5Y: 104.5" "Cancer enhanced" "Detected in some" "liver cancer: 1.9" "Region enriched" "Detected in single" 27 "pons and medulla: 9.7" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in some" 4 "pons and medulla: 8.2" "Region enriched" "Detected in single" 32 "pons and medulla: 23.1" "HPA004057, HPA076311, CAB078195" Enhanced Supported Approved Mitochondria,Cytosol Cytosol Mitochondria "CAB078195: , HPA004057: AB_1080012, HPA076311: " "unprognostic (9.58e-3)" "unprognostic (5.48e-2)" "unprognostic (1.26e-4)" "unprognostic (4.07e-1)" "unprognostic (4.16e-1)" "unprognostic (8.38e-2)" "unprognostic (2.97e-2)" "unprognostic (3.29e-1)" "unprognostic (2.31e-1)" "unprognostic (3.27e-1)" "unprognostic (2.12e-2)" "unprognostic (2.95e-2)" "unprognostic (1.72e-1)" "unprognostic (6.02e-2)" "unprognostic (8.48e-2)" "unprognostic (1.43e-2)" 2.4 20.4 0.3 0.1 0.1 0.0 1.8 0.1 0.3 3.2 0.3 0.3 0.1 0.0 4.5 7.2 0.8 0.4 0.4 0.1 0.1 0.0 0.4 1.0 0.5 0.1 0.1 0.1 0.2 0.1 0.0 0.1 41.8 9.7 0.5 0.1 0.1 1.6 1.7 0.1 11.4 0.4 1.0 0.2 0.1 0.2 8.3 0.2 0.1 0.2 0.9 0.5 0.5 1.7 0.0 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 1.0 0.8 104.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.1 0.3 0.1 0.0 0.1 0.1 9.7 0.2 SLITRK3 KIAA0848 ENSG00000121871 "SLIT and NTRK like family member 3" O94933 3 165186720-165197109 "Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 17.4;liver: 12.8" "Cell line enhanced" "Detected in some" "AF22: 6.5;HAP1: 5.4;Karpas-707: 1.5;SCLC-21H: 3.5" "Cancer enriched" "Detected in single" 22 "glioma: 7.1" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA017636, HPA048042" Enhanced Approved Mitochondria 1400000 Mitochondria "HPA017636: AB_1857232, HPA048042: " "unprognostic (8.91e-2)" "unprognostic (1.44e-1)" "unprognostic (4.08e-2)" "unprognostic (1.96e-1)" "unprognostic (5.16e-2)" "unprognostic (1.76e-1)" "unprognostic (9.59e-2)" "unprognostic (2.95e-2)" "unprognostic (1.03e-1)" "unprognostic (2.22e-1)" "unprognostic (6.74e-3)" "unprognostic (5.03e-1)" "unprognostic (2.38e-1)" "unprognostic (8.03e-4)" 0.6 0.6 7.4 2.0 12.0 0.4 0.5 10.6 17.4 9.9 3.0 1.5 0.3 1.1 12.1 2.0 7.6 12.6 0.8 1.0 13.2 5.5 0.6 12.8 0.9 0.5 3.7 6.5 2.5 0.4 0.4 0.3 0.4 4.2 3.3 3.1 0.3 0.8 9.6 0.9 0.5 1.5 6.2 2.3 0.4 0.8 1.0 2.4 0.0 0.6 0.0 0.5 0.9 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 5.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.7 0.0 1.0 0.1 0.0 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.4 12.0 10.6 15.7 13.2 5.5 3.7 6.5 4.2 2.4 SPAG9 "CT89, FLJ13450, FLJ14006, FLJ26141, FLJ34602, HLC4, HSS, JIP-4, JIP4, JLP, KIAA0516, MGC117291, MGC14967, MGC74461, PHET, PIG6, SYD1" ENSG00000008294 "Sperm associated antigen 9" O60271 17 50962174-51120865 "Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "basophil: 6.3;neutrophil: 13.4" "Lineage enriched" "Detected in many" 7 "granulocytes: 13.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA040446, HPA061458" Enhanced Enhanced "Centriolar satellite,Cytosol" "Centriolar satellite, Cytosol" "HPA040446: AB_10671691, HPA061458: " "unprognostic (1.36e-1)" "unprognostic (6.61e-2)" "unprognostic (6.04e-3)" "unprognostic (4.65e-2)" "unprognostic (3.52e-2)" "unprognostic (9.73e-2)" "unprognostic (8.13e-2)" "unprognostic (3.72e-2)" "unprognostic (1.90e-1)" "unprognostic (1.65e-1)" "unprognostic (2.83e-2)" "unprognostic (9.71e-2)" "unprognostic (2.23e-3)" "unprognostic (2.27e-2)" "unprognostic (9.53e-2)" "unprognostic (7.67e-2)" "prognostic unfavourable (8.10e-4)" 21.6 16.4 32.1 12.5 42.6 15.8 13.8 32.7 46.6 15.9 15.6 44.8 7.6 14.0 19.6 9.1 20.7 12.3 18.8 15.1 33.1 25.5 23.6 22.8 20.5 8.7 55.7 25.9 22.2 21.0 25.8 14.6 21.8 37.1 13.2 14.1 12.2 9.9 14.4 39.6 14.2 14.2 19.1 50.2 12.1 10.5 33.3 55.2 8.5 28.2 9.5 10.6 15.0 13.6 1.0 1.3 13.4 1.3 0.5 1.8 0.4 17.5 19.7 25.4 12.3 24.1 21.4 22.4 14.5 14.2 16.3 20.3 17.7 12.1 9.5 10.1 23.7 15.2 16.6 12.1 30.3 14.4 19.7 7.9 15.6 13.1 18.1 11.4 9.3 15.4 14.2 21.9 39.4 13.3 17.5 10.6 22.9 8.8 7.2 4.8 6.7 25.7 8.2 28.3 8.4 14.9 33.5 19.7 27.5 12.7 11.9 13.1 9.7 13.7 18.5 45.4 10.7 34.9 21.1 15.1 21.7 15.6 15.5 6.8 15.7 6.3 1.3 0.8 1.4 0.8 1.0 1.0 1.2 1.3 1.3 1.0 0.7 0.9 13.4 0.5 0.5 1.1 1.8 0.4 32.1 42.6 32.7 34.9 33.1 25.5 55.7 25.9 37.1 55.2 SPTBN4 "KIAA1642, SPTBN3" ENSG00000160460 "Spectrin beta, non-erythrocytic 4" Q9H254 19 40466241-40576464 "Disease related genes, Plasma proteins, Predicted intracellular proteins" "Actin capping, Actin-binding" "Deafness, Disease mutation, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 36.3" "Cell line enhanced" "Detected in some" "K-562: 3.5;Karpas-707: 5.0;SCLC-21H: 7.9;SH-SY5Y: 4.8" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA054481 Enhanced Approved Nucleoplasm,Nucleoli Nucleoli Nucleoplasm "HPA054481: " "unprognostic (1.97e-3)" "unprognostic (1.02e-1)" "unprognostic (5.65e-4)" "unprognostic (3.72e-4)" "unprognostic (7.79e-3)" "unprognostic (9.77e-2)" "unprognostic (2.62e-1)" "unprognostic (2.50e-2)" "unprognostic (3.19e-2)" "unprognostic (1.65e-1)" "unprognostic (1.78e-4)" "unprognostic (4.54e-1)" "unprognostic (2.55e-2)" "unprognostic (6.79e-2)" "unprognostic (1.42e-1)" "unprognostic (1.85e-2)" "unprognostic (2.02e-1)" 3.1 5.9 13.4 1.2 15.3 1.2 1.2 36.3 27.1 1.4 1.3 1.8 0.0 1.7 2.3 1.3 1.6 2.0 1.8 3.3 9.8 10.8 1.9 1.3 1.2 1.0 7.5 13.0 4.1 3.0 3.3 8.0 1.0 10.4 2.8 1.1 2.6 2.2 2.0 5.1 1.3 1.5 1.8 2.8 1.3 2.5 3.5 3.7 0.0 1.6 0.0 1.0 1.2 0.5 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 1.5 0.0 0.2 0.1 0.0 0.0 0.2 0.0 0.1 0.1 0.0 0.4 2.3 1.9 0.4 0.0 0.0 0.0 0.0 0.4 2.3 0.5 0.0 0.0 0.3 0.0 0.8 0.3 0.0 0.0 0.0 0.0 3.5 5.0 0.0 1.3 0.0 0.0 0.2 0.8 0.5 0.0 1.1 0.0 0.0 7.9 4.8 0.1 0.2 0.0 0.7 0.0 0.0 0.0 1.4 0.8 0.0 0.2 0.3 0.3 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.4 15.3 36.3 22.7 9.8 10.8 7.5 13.0 10.4 3.7 STXBP6 "amisyn, HSPC156" ENSG00000168952 "Syntaxin binding protein 6" Q8NFX7 14 24809656-25050297 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "CACO-2: 19.5;Daudi: 20.2;HBF TERT88: 26.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 3.7" "Group enriched" "Detected in many" 12 "dendritic cells: 2.0;T-cells: 3.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA003552, HPA074869" Approved "HPA003552: AB_10603343, HPA074869: " "unprognostic (1.52e-1)" "unprognostic (2.73e-1)" "unprognostic (2.54e-2)" "unprognostic (1.20e-2)" "unprognostic (9.01e-2)" "unprognostic (2.28e-2)" "unprognostic (1.05e-1)" "unprognostic (2.37e-2)" "unprognostic (1.69e-1)" "unprognostic (6.46e-3)" "unprognostic (1.51e-1)" "unprognostic (6.73e-3)" "unprognostic (5.10e-3)" "unprognostic (1.16e-1)" "unprognostic (1.43e-1)" "unprognostic (1.36e-1)" "unprognostic (1.48e-3)" 5.3 0.9 12.9 2.9 17.5 0.4 3.8 1.5 20.0 10.7 9.9 13.2 5.4 9.4 6.0 30.2 5.0 5.7 8.6 12.6 11.9 11.9 3.2 4.1 16.7 1.4 10.7 13.2 2.6 34.1 5.9 1.2 31.6 13.8 10.0 11.5 2.1 10.0 8.1 3.2 10.0 13.9 10.4 14.2 0.9 7.4 3.4 11.5 0.4 14.0 1.7 4.2 8.4 5.7 0.2 2.0 0.0 0.0 0.0 3.7 0.7 0.0 0.4 0.8 0.2 5.4 9.5 0.0 6.1 16.4 14.7 15.7 19.5 0.1 20.2 0.0 17.1 0.0 0.0 0.0 26.9 10.7 1.3 4.8 0.1 14.6 4.0 0.3 2.6 1.4 0.0 0.0 0.0 0.0 0.2 7.0 13.9 3.8 0.1 0.0 2.7 0.0 0.0 11.6 0.1 0.0 1.1 0.9 0.0 0.0 3.2 16.9 0.2 0.3 0.0 2.6 7.1 17.0 0.8 2.1 2.3 0.9 9.1 0.1 9.8 0.0 0.0 0.0 3.7 0.0 0.8 0.2 0.5 0.3 0.0 0.0 0.0 1.7 0.0 0.0 0.0 2.0 0.0 0.7 12.9 17.5 1.5 20.0 11.9 11.9 10.7 13.2 13.8 11.5 TAC1 "NKNA, NPK, TAC2" ENSG00000006128 "Tachykinin precursor 1" P20366 7 97731908-97740472 "Predicted secreted proteins" "Neuropeptide, Neurotransmitter" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "brain: 61.3;lymphoid tissue: 62.9" "Cell line enriched" "Detected in some" 19 "U-266/70: 22.0" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in many" "basal ganglia: 61.3" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in many" "basal ganglia: 557.4" "Region enriched" "Detected in many" 9 "basal ganglia: 312.7" HPA014429 Enhanced "Secreted to blood" "HPA014429: AB_1857722" "unprognostic (9.24e-3)" "unprognostic (2.65e-2)" "unprognostic (1.84e-1)" "unprognostic (1.19e-1)" "unprognostic (1.92e-1)" "unprognostic (2.08e-1)" "unprognostic (7.95e-2)" "unprognostic (3.24e-1)" "unprognostic (1.70e-2)" "unprognostic (3.21e-2)" "unprognostic (1.70e-1)" "unprognostic (1.69e-1)" "unprognostic (3.86e-2)" 1.8 6.5 4.1 7.7 61.3 0.3 1.7 0.3 39.8 0.7 3.7 0.1 0.0 6.0 0.9 1.6 0.3 0.7 4.9 0.5 9.3 21.5 1.6 0.6 0.3 0.3 8.0 4.5 0.3 0.7 0.3 0.3 0.3 24.5 1.0 2.9 0.3 4.5 2.0 0.4 1.2 7.6 5.3 6.7 62.9 0.9 0.6 9.4 0.0 1.6 0.0 0.3 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 22.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.1 61.3 0.3 9.2 9.3 21.5 8.0 4.5 24.5 9.4 TBR1 ENSG00000136535 "T-box, brain 1" Q16650 2 161416094-161425870 "Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Autism spectrum disorder, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 26 "brain: 34.9" "Cell line enhanced" "Detected in some" "HAP1: 1.6;HMC-1: 1.3;Karpas-707: 1.0;SCLC-21H: 1.7;U-266/84: 1.5" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 6 "amygdala: 45.6;basal ganglia: 28.5;cerebral cortex: 70.3;hippocampal formation: 50.1" "Region enhanced" "Detected in many" "cerebral cortex: 63.6" "HPA051256, HPA078644, HPA078657" Enhanced Supported "HPA051256: , HPA078644: AB_2732387, HPA078657: AB_2732388" "unprognostic (3.08e-2)" "unprognostic (5.45e-2)" "unprognostic (1.13e-1)" "unprognostic (1.35e-2)" "unprognostic (7.43e-3)" "unprognostic (1.95e-1)" "unprognostic (1.83e-2)" "unprognostic (1.14e-1)" "unprognostic (1.39e-9)" "unprognostic (5.72e-2)" "unprognostic (1.72e-1)" "unprognostic (5.37e-2)" 0.6 0.5 11.2 0.5 13.7 0.5 0.5 0.3 34.9 0.6 0.5 0.0 0.0 0.5 0.5 0.6 0.5 0.6 0.5 0.5 6.1 1.3 0.5 0.5 0.5 0.5 0.8 21.0 0.5 0.6 0.6 0.3 0.5 0.0 0.5 0.6 0.0 0.5 0.7 0.5 0.5 0.5 0.5 0.4 0.5 0.5 1.3 0.0 0.0 0.5 0.0 0.5 0.5 0.3 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 1.6 0.0 0.1 0.3 0.0 0.1 0.1 0.0 0.0 0.0 1.3 0.0 0.2 0.2 0.0 0.0 0.1 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 1.7 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.6 0.0 0.2 0.5 1.5 0.0 0.2 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 11.2 13.7 0.3 34.9 6.1 1.3 0.8 21.0 0.0 0.0 TMEM145 FLJ90805 ENSG00000167619 "Transmembrane protein 145" Q8NBT3 19 42313325-42325062 "Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in many" 5 "brain: 74.5" "Cell line enhanced" "Detected in many" "HMC-1: 11.7;SCLC-21H: 22.2;SH-SY5Y: 10.6" "Cancer enhanced" "Detected in many" "glioma: 8.8" "Region enriched" "Detected in all" 4 "cerebellum: 74.5" "Group enriched" "Detected in some" 8 "basophil: 4.5;neutrophil: 15.5" "Lineage enriched" "Detected in many" 12 "granulocytes: 15.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA060462 Enhanced Approved Approved Vesicles Vesicles "HPA060462: " "unprognostic (9.56e-3)" "unprognostic (8.61e-2)" "unprognostic (6.65e-2)" "unprognostic (1.19e-1)" "unprognostic (2.96e-1)" "unprognostic (3.02e-1)" "unprognostic (1.47e-1)" "unprognostic (6.62e-2)" "unprognostic (2.14e-1)" "unprognostic (4.27e-3)" "unprognostic (1.53e-2)" "unprognostic (9.85e-2)" "unprognostic (4.20e-4)" "unprognostic (7.35e-2)" "unprognostic (7.64e-2)" "unprognostic (2.30e-1)" "unprognostic (6.31e-2)" 1.6 6.2 8.0 1.2 7.7 2.5 1.3 74.5 30.5 0.6 1.2 3.8 0.0 1.7 1.1 1.6 1.0 1.1 1.4 1.3 5.8 8.5 0.9 1.4 0.8 1.5 5.1 7.6 1.2 3.7 3.0 6.4 0.6 9.3 1.2 1.2 2.8 1.1 0.9 2.3 3.3 1.1 1.2 3.9 1.5 2.0 3.3 3.2 0.0 1.3 0.0 1.1 1.0 0.3 1.3 0.8 15.5 0.9 0.6 0.9 0.8 0.5 2.7 2.1 6.4 0.2 0.2 0.8 0.2 0.1 1.0 2.6 0.5 0.7 1.5 0.3 0.6 0.2 1.5 0.4 1.2 6.7 1.6 2.8 2.5 2.4 0.2 1.6 11.7 0.5 0.5 0.4 0.6 1.1 1.5 5.5 0.1 0.6 0.4 1.9 1.3 8.6 0.2 0.6 5.2 0.1 1.0 22.2 10.6 0.9 0.7 1.3 1.9 1.8 0.3 1.8 1.9 1.3 0.7 1.2 3.0 1.4 0.7 1.1 5.1 4.5 0.9 0.9 0.6 0.8 0.3 1.0 0.6 0.4 0.2 1.3 0.6 0.9 15.5 0.6 0.7 0.8 0.4 0.8 8.0 7.7 74.5 18.1 5.8 8.5 5.1 7.6 9.3 3.2 TMEM169 FLJ34263 ENSG00000163449 "Transmembrane protein 169" Q96HH4 2 216081866-216102783 "Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 16.8" "Cell line enhanced" "Detected in some" "AF22: 8.3;LHCN-M2: 6.7;RPTEC TERT1: 12.2;SCLC-21H: 10.5;SH-SY5Y: 15.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA062462, HPA062797, HPA070657, HPA074877" Enhanced Approved Nucleoplasm,Centrosome,Cytosol "Nucleoplasm, Cytosol" Centrosome "HPA062462: , HPA062797: , HPA070657: , HPA074877: " "unprognostic (5.15e-2)" "unprognostic (2.93e-1)" "unprognostic (7.87e-3)" "unprognostic (4.69e-7)" "unprognostic (4.26e-2)" "unprognostic (1.17e-1)" "unprognostic (1.97e-1)" "unprognostic (4.43e-1)" "unprognostic (7.16e-2)" "unprognostic (5.72e-2)" "unprognostic (1.00e-1)" "unprognostic (1.35e-1)" "unprognostic (2.79e-2)" "unprognostic (7.51e-3)" "unprognostic (4.69e-2)" "unprognostic (1.54e-1)" "unprognostic (1.02e-1)" 1.7 2.9 5.9 2.5 6.2 1.3 0.9 9.7 16.8 2.1 1.3 3.9 1.6 1.9 1.1 1.9 0.9 2.9 2.5 1.1 5.5 6.3 4.9 4.2 2.1 2.4 5.5 4.8 1.1 1.0 0.8 2.4 0.7 9.1 1.4 1.2 4.9 0.9 1.1 1.5 1.6 1.7 1.2 6.6 2.6 1.0 1.3 2.5 0.7 6.7 0.0 2.0 1.1 0.7 3.0 0.2 4.3 5.7 0.7 6.3 1.3 0.1 0.4 8.3 0.2 0.9 0.1 0.0 0.3 0.2 0.2 0.8 0.4 2.4 0.1 6.1 0.3 0.2 1.1 0.0 0.2 1.2 0.4 2.7 0.1 1.5 1.8 0.2 0.6 0.6 0.6 0.6 0.8 0.0 0.0 0.4 6.7 0.7 0.2 0.3 4.3 0.1 1.5 2.4 0.2 12.2 0.0 10.5 15.1 0.2 0.2 6.0 0.4 1.1 0.1 0.2 0.4 0.2 0.4 1.9 2.0 0.4 1.9 0.2 1.5 1.3 1.8 0.3 2.3 1.5 1.7 2.4 4.0 2.7 0.0 3.0 4.2 1.9 4.3 0.7 5.7 0.2 6.3 1.3 5.9 6.2 9.7 11.5 5.5 6.3 5.5 4.8 9.1 2.5 TPPP3 "CGI-38, p20, p25gamma" ENSG00000159713 "Tubulin polymerization promoting protein family member 3" Q9BW30 16 67389809-67393535 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "fallopian tube: 211.3" "Cell line enhanced" "Detected in some" "A549: 29.6;RH-30: 15.8;SCLC-21H: 24.4;SH-SY5Y: 10.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "non-classical monocyte: 26.2" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA047629, HPA061691" Enhanced Approved "Nucleoli fibrillar center" 29000 "Nucleoli fibrillar center" "HPA047629: , HPA061691: " "unprognostic (1.63e-1)" "unprognostic (6.62e-3)" "unprognostic (1.35e-1)" "unprognostic (7.28e-3)" "unprognostic (4.48e-3)" "unprognostic (1.59e-3)" "unprognostic (9.22e-2)" "unprognostic (3.23e-1)" "unprognostic (1.46e-2)" "unprognostic (2.93e-2)" "unprognostic (1.02e-3)" "unprognostic (7.98e-2)" "prognostic unfavourable (8.84e-4)" "unprognostic (3.51e-2)" "unprognostic (9.44e-2)" "unprognostic (9.46e-2)" "unprognostic (1.86e-3)" 9.6 7.6 30.5 2.9 20.7 1.0 21.9 3.7 25.0 12.8 11.9 70.3 2.0 6.4 7.2 15.1 24.8 211.3 6.0 11.3 36.4 41.9 6.1 1.9 36.3 1.7 26.4 22.1 14.1 6.5 2.2 5.8 70.6 24.5 3.4 4.3 2.2 5.2 4.2 14.4 28.1 9.8 10.0 40.6 3.8 11.3 2.6 24.4 0.1 3.5 37.6 6.1 7.4 5.5 0.0 14.1 5.2 26.2 0.0 0.1 3.6 0.2 29.6 0.3 0.2 0.2 4.9 0.1 0.8 0.2 0.2 0.4 1.9 6.0 0.0 0.4 0.4 5.6 4.6 0.0 0.0 0.0 1.7 0.0 0.8 0.8 0.0 0.0 0.0 1.2 0.1 1.8 0.0 0.3 0.0 0.0 2.7 0.1 0.0 0.1 1.0 0.0 0.0 15.8 0.1 0.0 0.0 24.4 10.5 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.3 0.3 0.0 0.0 0.0 0.0 1.5 0.0 0.4 0.0 10.9 5.2 0.0 15.4 0.1 0.0 0.0 0.0 14.1 0.0 0.0 0.0 2.6 0.0 26.2 0.1 0.0 3.6 30.5 20.7 3.7 23.8 36.4 41.9 26.4 22.1 24.5 24.4 TTC21B "FLJ11457, IFT139B, JBTS11, NPHP12, THM1" ENSG00000123607 "Tetratricopeptide repeat domain 21B" Q7Z4L5 2 165857475-165953843 "Disease related genes, Predicted intracellular proteins" "Ciliopathy, Disease mutation, Joubert syndrome, Meckel syndrome, Mental retardation, Nephronophthisis, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA035494, HPA035495, HPA073293" Supported Supported Mitochondria Mitochondria "HPA035494: , HPA035495: AB_10672866, HPA073293: " "unprognostic (1.63e-2)" "unprognostic (1.17e-1)" "unprognostic (3.10e-1)" "unprognostic (1.60e-2)" "unprognostic (2.96e-1)" "unprognostic (2.51e-1)" "unprognostic (7.09e-3)" "unprognostic (2.81e-2)" "unprognostic (2.98e-2)" "unprognostic (7.57e-2)" "unprognostic (3.52e-2)" "unprognostic (3.29e-1)" "prognostic unfavourable (1.36e-4)" "unprognostic (1.32e-1)" "unprognostic (1.55e-1)" "unprognostic (2.37e-2)" "unprognostic (1.84e-2)" 10.4 9.0 11.3 7.0 18.3 8.6 11.7 39.6 19.8 12.3 9.2 7.1 5.3 6.5 13.8 10.0 6.7 15.3 7.5 10.4 10.1 8.1 12.5 8.9 9.4 8.9 12.3 11.9 17.5 10.1 10.4 17.6 9.8 15.7 14.9 8.9 6.3 9.1 10.2 16.4 10.7 8.2 9.7 12.2 8.4 8.5 9.7 13.8 16.2 9.4 7.1 8.0 9.8 11.8 3.8 3.1 8.7 2.7 3.7 4.7 1.8 4.9 3.8 17.4 7.1 11.8 11.4 4.6 9.9 8.1 8.0 7.9 5.4 3.3 11.5 6.0 7.0 5.2 11.7 6.2 9.5 8.0 5.8 9.4 6.7 13.1 6.9 8.8 0.0 6.2 4.0 9.2 6.7 8.6 12.4 8.7 10.1 2.7 10.8 7.0 7.2 9.4 12.0 14.0 3.9 6.2 10.6 12.5 7.3 7.8 1.9 8.7 2.9 6.3 6.3 14.1 6.3 7.8 7.3 5.0 7.0 10.6 5.9 5.5 8.8 8.7 1.9 3.3 2.9 2.3 4.2 3.8 3.4 2.9 3.1 3.2 4.4 4.7 0.8 3.7 2.7 1.6 4.2 1.8 11.3 18.3 39.6 19.8 10.1 8.1 12.3 11.9 15.7 13.8 ZNF365 "KIAA0844, UAN" ENSG00000138311 "Zinc finger protein 365" "Q70YC4, Q70YC5" 10 62374192-62672011 "Disease related genes, Predicted intracellular proteins" Neurogenesis "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 41.3" "Cell line enhanced" "Detected in many" "HaCaT: 17.2;PC-3: 11.1;U-251 MG: 14.3;U-87 MG: 10.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 8 "gdT-cell: 3.4;memory CD4 T-cell: 3.1;memory CD8 T-cell: 3.5;naive CD8 T-cell: 3.7;NK-cell: 7.4;T-reg: 7.5" "Group enriched" "Detected in many" 51 "NK-cells: 7.4;T-cells: 7.5" "Group enriched" "Detected in all" 4 "amygdala: 328.0;basal ganglia: 309.9;cerebral cortex: 424.1;hippocampal formation: 348.1;thalamus: 127.9" "Low region specificity" "Detected in all" HPA052446 Enhanced Supported "Vesicles,Centriolar satellite" "Vesicles, Centriolar satellite" "HPA052446: " "unprognostic (7.46e-2)" "unprognostic (1.42e-1)" "unprognostic (1.36e-1)" "unprognostic (1.26e-3)" "unprognostic (1.21e-1)" "unprognostic (4.05e-3)" "unprognostic (1.73e-1)" "unprognostic (7.67e-2)" "unprognostic (2.15e-2)" "unprognostic (3.11e-3)" "unprognostic (3.06e-2)" "unprognostic (7.90e-2)" "unprognostic (1.12e-6)" "unprognostic (2.49e-3)" "unprognostic (1.58e-1)" "unprognostic (1.20e-4)" "unprognostic (2.89e-2)" 0.9 2.5 11.8 1.0 19.4 1.0 1.3 8.4 41.3 2.0 0.9 13.1 0.0 1.1 1.2 1.5 11.7 1.0 4.0 2.0 9.6 7.4 1.1 1.2 3.1 1.1 7.5 16.0 1.0 1.3 9.0 1.8 1.2 6.9 3.0 1.1 1.0 1.2 3.3 1.0 2.6 0.9 0.9 10.5 1.3 1.0 1.6 9.1 0.0 1.6 0.0 2.2 1.9 1.2 0.1 0.0 0.1 0.1 7.4 7.5 1.0 5.7 0.8 0.5 0.7 0.6 0.3 0.3 4.3 4.5 2.2 1.9 0.6 1.4 0.4 0.7 2.6 17.2 0.5 0.3 2.9 0.2 0.4 0.3 1.5 0.4 0.2 0.3 1.4 0.3 0.3 5.8 0.8 0.7 0.4 0.6 4.2 2.1 0.7 0.5 0.8 11.1 0.4 0.5 0.4 0.5 2.6 0.2 0.9 1.1 0.9 0.4 0.1 0.3 3.1 1.2 5.6 0.6 14.3 0.2 0.5 0.3 10.2 0.6 1.9 0.0 0.0 0.0 3.4 0.1 0.0 0.0 3.1 3.5 0.0 0.1 0.6 3.7 0.1 7.4 0.1 0.0 7.5 1.0 11.8 19.4 8.4 32.3 9.6 7.4 7.5 16.0 6.9 9.1